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Abstract: The recent failure of candidate drugs like cholesterol ester transfer protein (CETP) and acyl-CoA:cholesterol 
acyltransferase (ACAT) inhibitors calls for a revised approach for screening anti-atherosclerotic drugs and development of 
new models of atherosclerosis. For this it is important to understand the mechanism of the disease in a particular model. 
Models simultaneously showing hyperlipidemia, inflammation and associated complications of diabetes and hypertension 
will serve the purpose better as they mimic the actual clinical condition. Besides this, analyzing candidate molecules in 
vivo, in vitro and at various levels of atherosclerosis progression is important. Models based on various cells and process 
involved in atherosclerosis should be used for screening candidate molecules. The challenge lies in bridging the gap be-
tween genetically friendly small animal and human-like bigger animal models. Sequencing of the mouse and human ge-
nome, development of a single nucleotide polymorphism (SNP) database and in silico quantitative trait loci (QTL) linkage 
analysis may enhance the understanding of atherosclerosis and help develop new therapeutic targets.  
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INTRODUCTION 
 Atherosclerosis is a complex disorder [1-4]. Initial events 
include endothelial injury and monocyte activation [5, 6]. 
However the type and stimulus of injury triggering athero-
sclerosis is still an area of active research [5, 6]. With the 
help of various cell adhesion molecules and gap junctions, 
leukocytes adhere and migrate in to the endothelium [5, 6]. 
Monocytes differentiate into macrophages inside the vessel 
wall and form macrophage foam cells [5-7]. These cells in-
teract with other cells like T lymphocytes [5, 6] and vascular 
smooth muscle cells (VSMCs) [5, 6], which migrate [5, 6], 
differentiate [5, 6] and proliferate [5, 6] and take positions in 
close proximity to these cells [5, 6]. Amplification of the 
inflammatory response [5, 6] coupled with enhanced migra-
tion, proliferation and differentiation of inflammatory cells 
accounts for atherosclerosis progression [5, 6]. Secretion of 
various extra cellular matrix proteins by VSMC ultimately 
leads to the formation of fibrous plaque [5, 6]. Vessel micro-
environment is compromised due to extensive biochemical 
and molecular changes and beneficial processes like phago-
cytic clearance of lipid-laden macrophages is hampered [5, 
6]. Under such conditions cells undergo necrotic death and 
release various inflammatory cytokines, lipids, and cellular 
content to form a lipid rich necrotic core [5, 6]. All these 
processes contribute to the formation of an atherosclerotic 
plaque [5, 6]. Unstable plaques are prone to rupture due to 
degradation of extracellular matrix proteins by released met-
alloproteases [5, 6] leading to various complications, de-
pending on the site of vessel blockage [5, 6]. This leads to 
exposure of blood to tissue factor (TF), thus activating the 
coagulation cascade and fibrin deposition and activating and 
recruiting platelets to form a thrombus [5, 6].  
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 This review covers all the aspects of models of athero-
sclerosis. This includes animal models [8-12], lower organ-
isms [13] genetic models [14], in silico [14, 15], analytical 
[16], kinetic models [17], in vitro models and also target-
based models. The importance of target-based models can be 
derived from the mechanism of atherosclerosis discussed in 
the review. Thus, it addresses not only the model but also the 
mechanism of disease manifestation in them. It also de-
scribes in brief how these models can be used for the as-
sessment of various drugs. Although reviews on animal mo-
dels of atherosclerosis have been published [18-24], there are 
almost none for the in vitro, cell and target based models, 
which this review will cover. Besides updating all the mod-
els, the present review approaches the models in a mechanis-
tic way and thus blends classical animal models with recent 
biochemical and molecular findings. This will help in under-
standing the disease process and designing better strategies 
including models to study atherosclerosis.  
ATHEROSCLEROSIS: COMPLICATIONS AND FAI-
LURES  
 Failure of ACAT [25-28], and CETP [29] inhibitors are a 
setback in the treatment of atherosclerosis. These observa-
tions emphasize the fact that a candidate molecule should 
show a protective effect in several models of atherosclerosis. 
Furthermore, studying a disorder in isolation may not lead to 
clinically relevant benefits. It is often observed that those 
suffering from atherosclerosis, also have diabetes and insulin 
resistance [4, 30-32]. More evidence for this concept comes 
from many basic [33, 34] and clinical observations [4, 32, 
35, 36]. Dyslipidemic patients suffering from diabetes and 
insulin resistance may show better cardiovascular improve-
ment than the dyslipidemic alone, when treated with PPAR 
(peroxisome proliferator-activated receptor) ? agonists [6, 
37]. Similarly thrombotic events observed in atherosclerosis 
[38-42] and the common use of anti-platelet drugs in patients 
who have undergone balloon angioplasty emphasizes that 
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thrombosis is central to atherosclerotic complications [43-
46]. Similar findings have shown that anti-platelet drug-
eluting stents to be more protective against restenosis in 
atherosclerotic patients suffering from diabetes [47]. How-
ever, it can also be argued at the same time that since the 
incidence of restenosis is more in diabetics, the chances of 
seeing protection is more. 
 The existence of hypertension along with atherosclerosis 
is common [48-50] with evidence that shear stress influences 
the development of atherosclerosis [49, 51, 52]. Activation 
of the renin-angiotensin system (RAS) in adipose tissue may 
represent an important link between obesity and hyperten-
sion [53]. Plasma-derived angiotensin II (AngII) exerts po-
tent vasoconstrictor effects on resistance arteries. In addition 
Ang II releases aldosterone from the adrenal glands, which 
in turn enhances renal tubular sodium reabsorption resulting 
in an increase in the effective plasma volume [54, 55]. Other 
proatherosclerotic effects of angiotensin have also been rec-
ognised [55, 56]. The potential link between Ang II and athe-
rosclerosis is strengthened by the Heart Outcomes Preven-
tion Evaluation (HOPE) trial where ACE (angiotensin con-
verting enzyme) inhibition reduced the rates of death, myo-
cardial infarction, and stroke in patients with atherosclerosis 
[57]. 
 The effectiveness of statins [3-hydroxy-3-methylglutaryl 
coenzyme A (HMG CoA) reductase inhibitors] faces the fact 
that many patients who develop atherosclerosis have choles-
terol below risk levels [58]. At the same time there is evi-
dence that the protection exerted by statins is not only due to 
cholesterol lowering but also to other actions like inflamma-
tion, which plays a role in atherosclerosis progression [59, 
60]. Thus, it is important to develop models of atherosclero-
sis that comprehensively reflect the clinical situation. A dif-
ferent mechanism of atherosclerosis in different animals may 
explain certain failures. For example, drugs affecting the 
reverse cholesterol transport (RCT) that are also in clinical 
trials [61, 62]. However, while screening these candidate 
drugs in animals one has to be careful of the interpretations. 
An example of this is CETP. This is a protein involved in 
human RCT but it is absent in mice [63, 64]. It follows that a 
candidate drug showing good results with respect to RCT in 
a mouse model, may behave differently in humans. Attrac-
tive molecules like the CETP inhibitor torcetrapib have faced 
failure in clinical trialls and it is still being debated whether 
it was the mechanism or the structure of the molecule, which 
lead to its failure [29]. A combination of atorvastatin with 
torcetrapib lead to increased myocardial infarction, angina, 
heart failure, revascularization procedures when compared 
with atorvastatin alone [29]. However, in an other study, 
although there was no protection with the candidate drug, no 
major adverse effects were noticed [65]. This may be a struc-
ture specific effect. At the same time lipoprotein a [Lp(a)] is 
absent in mice and many other animals [66]. Therefore, the 
species specific presence/absence of these proteins will af-
fect the candidate drug is unknown until evaluated in a clini-
cal setting. 
 ACAT inhibitors are facing failures in clinical trials even 
after more than 2 decades of research [25-28]. ACAT2 es-
terifies the free cholesterol that forms the core of lipoproteins 
assembled in hepatocytes and intestinal epithelium, whereas 
ACAT1 acts in macrophages [25]. Several ACAT inhibitors 
failed in clinical trials after showing very promising results 
in animal models [25-28]. This raises the question about the 
suitability of the models used. Time of animal sacrifice and 
the sites of lesion analysis may determine outcome [25, 67-
72]. Evidence suggests that different lesion sites may re-
spond differently to the same drug [67]. Therefore, it is im-
portant that the lesion being analyzed should be similar to 
humans in its nature and location [67]. Equal importance to 
plasma lipid levels has to be given and mere significant 
changes are not sufficient [67]. Lesion analysis at varying 
plasma lipid levels may yield variable results. These points 
are also important when comparing data from 2 different 
studies. Answer to the failures also comes from the data re-
garding the overall effect of these inhibitors [25, 67-72]. 
Although ACAT inhibitors make more cholesterol available 
for RCT, too much of it can induces macrophage apoptosis 
and plaque rupture in atherosclerosis [73-76]. Screening of 
these inhibitors in animals, which can take care of excess 
cholesterol easily or have upregulated RCT and cholesterol 
efflux may provide inappropriate projections about the can-
didate molecules [25]. Therefore, while screening for ACAT 
inhibitors it also becomes important to ascertain the extent of 
cholesterol-induced apoptosis. However, if used in combina-
tion with inhibitors of apoptosis or activators of cholesterol 
efflux, these inhibitors may work but this also requires clini-
cal testing.  
 Therefore, understanding the mechanism of atherosclero-
sis is a key factor. 
MECHANISM OF ATHEROSCLEROSIS  
 Different biochemical and molecular events control the 
various processes of atherosclerosis, making it a very com-
plex process [5, 6]. Activated monocytes adhere to the endo-
thelium with the help of cell adhesion molecules and recep-
tors like intercellular cell adhesion molecule (ICAM), vascu-
lar cell adhesion molecule (VCAM), selectins, very late anti-
gen-4 (VLA-4) [5, 6]. This process involves distinct signal-
ing mechanisms which leads to upregulation of cell adhesion 
molecules and receptors and gap junctions like connexin 
(Cx) 37 on the endothelium and monocytes [5, 6, 77]. Leu-
kocyte rolling (L-selectin, P-selectin), arrest (E-selectin, 
Cx57, VCAM-1, ICAM-1) and diapedesis [ICAM-1, Plate-
let/endothelial cell adhesion molecule-1 (PECAM-1), junc-
tional adhesion molecule-A (JAM-A), Cx 43] leads to their 
accumulation inside the endothelium [78, 79]. These adhe-
sion molecules and gap junctions are potential therapeutic 
targets as are the cellular signaling like activation family of 
protooncogenic tyrosine kinases (src kinases), phosphoinosi-
tide 3 (PI3) kinase -AKT, p38 mitogen activated protein 
kinase (p38 MAPK) and nuclear factor-kappa B (NFkB) that 
are associated with their upregulation [6, 80-85]. 
 Macrophage chemotactic protein-1 (MCP-1) and macro-
phage migration inhibitory factor (MIF) play an important 
role in monocyte activation, migration and differentiation [6, 
81, 82, 86-90]. MCP-1 receptor, C-C motif chemokine re-
ceptor–2 (CCR2) knockouts show reduced atherosclerosis 
[82]. MIF and chemokine receptor also play an important 
role in the chemotaxis and upregulation of cell adhesion 
molecule [6, 84, 91] and are areas of future therapeutic inter-
vention [6, 78, 92]. An inflammatory response seems to am-
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plify these processes [5, 6]. Once inside the vessel wall 
monocytes differentiate into macrophages in presence of 
macrophage-colony stimulating factor (M-CSF), granulocyte 
macrophage colony stimulating- factor (GM-CSF) and modi-
fied lipids [5, 6]. These differentiated macrophages accumu-
late modified lipids via specific receptors like macrophage 
scavenger receptor (SR) A, CD36 and lectin-like oxidized 
low-density lipoprotein receptor-1 (LOX-1) [5, 6] and pino-
cytosis [93]. All of these are areas of active research and 
being developed as targets of atherosclerosis. Enzymes like 
lipoxygenase (LOX) 15, 5LOX and inducible nitric oxide 
synthase (iNOS) bring about oxidation of low density lipo-
protein (LDL) to form oxidized low density lipoprotein (Ox-
LDL) [5, 6]. iNOS, NADPH oxidase, cyclooxygenase 
(COX), LOX12/15 and mitochondrial dysfunction contribute 
to free radical generation and protein modifications observed 
during atherosclerosis [5, 6]. Since oxidative stress contrib-
utes to atherosclerosis progression, several antioxidants are 
in clinical trials for this disorder [94]. Use of COX-2 inhibi-
tors is often accompanied with myocardial infarction and 
thus it has a major drawback [95]. It is believed that selective 
COX-2 inhibition disturbs the thrombotic equilibrium and 
creates an imbalance between anti and pro-thrombotic fac-
tors by inhibiting endothelium-derived prostaglandin (PG) I2 
while sparing platelet-derived thromboxane [95]. 
 The endothelium [96] promotes anti-thrombotic events 
by releasing nitric oxide (NO), prostacyclin (PGI2), adeno-
sine nucleotides which inhibit platelet adhesion and aggrega-
tion [96]. Tissue factor pathway inhibitor (TFPI), thrombo-
modulin (TM), heparans and dermatans released by the ves-
sel wall are inhibitors of the coagulation pathway [96]. Tis-
sue plasminogen activator (tPA) and urokinase-type plasmi-
nogen activator (uPA) bring about fibrin cleavage [96] and 
NO and interleukin (IL)-10 suppresses adhesion and aggre-
gation of blood platelets [96]. However, at the same time 
mediators like von Willebrand factor (vWF), P-selectin and 
IL-8 released by the endothelium promote platelet activation 
and prothrombotic events [96]. TF, factor Va, phosphatidyl-
serine activate the coagulation cascade [96]. Plasminogen 
activator inhibitor-1 (PAI-1) is involved in fibrinolysis [96]. 
Adhesion molecules, inflammatory mediators like tumor 
necrosis factor (TNF) ? and CD40L released by platelets and 
endothelium promote formation of platelet leukocyte co-
aggregate and thrombosis [96]. Platelet activation, besides 
creating a prothrombotic environment [36, 97] also leads to 
an increase in platelet-derived growth factor (PDGF), lys-
ophosphatidic acid (LPA) and 5-hydroxytryptamine (5-HT). 
These agents promote smooth muscle cell (SMC) migration 
and proliferation [36, 97]. 
 Inside the macrophages, the enzyme ACAT-1 converts 
free cholesterol, released as a result of lysosomal degrada-
tion, into cholesterol esters [7]. These give macrophages the 
characteristic foamy appearance and hence the name “foam 
cell” [7]. All cells including endothelium, macrophages and 
VSMCs accumulate these lipids to form foam cells, which 
ultimately contributes to the formation of atherosclerotic 
plaque [98, 99]. Oxidative stress contributes to foam cell 
formation by generating more oxidized lipids [5, 100]. Re-
cently c-jun-N-terminal kinase-2 (JNK2) has been postulated 
to play a role in macrophage foam cell formation and athero-
sclerosis progression [6, 101]. A similar enzyme, ACAT2, 
present in the intestine, facilitates the uptake of chylomicrons 
[27]. Cholesterol inside the macrophages is routinely ex-
pelled by transporters like ATP-binding cassette transporter 
A1 (ABCA1), ATP binding cassette transporter G1 
(ABCG1), SR B1, caveolins and sterol 27-hydroxylase to 
acceptors like HDL and apolipoprotein (Apo) A-1 [102]. 
This forms an important step of RCT a process by which 
excess cholesterol is removed from the macrophage and ves-
sel wall to the liver or intestine for metabolism and excretion 
[102]. Although several proteins mediate the processing and 
uptake of effluxed cholesterol before it is finally excreted 
from the liver, HDL takes center stage in this process and 
therapeutic interventions targeting this process have a bear-
ing on the plasma HDL-cholesterol levels [103-106]. It is 
well understood that from the early days of the Framingham 
Heart Study, that HDL-cholesterol levels are a more potent 
risk factor for coronary artery disease than LDL-cholesterol, 
total cholesterol or plasma triglyceride [107, 108]. Therefore, 
strategies affecting the RCT in such a way so as to increase 
the HDL-cholesterol are being actively pursued [103-106]. 
Apo A1 forms nascent discoidal HDL (ndHDL) particles on 
reacting with serum phospholipids [102]. This is an acceptor 
of effluxed cholesterol from macrophages and endothelium 
and is esterified by the enzyme lecithin: cholesterol acyl 
transferase (LCAT) [102]. Further action by enzymes like 
phospholipid transfer protein (PLTP) leads to formation of 
more mature HDL particles (HDL2) [102]. PLTP also has a 
role in generating pre ?-HDL, which is an important acceptor 
of cholesterol at the plasma membrane of the effluxing cells 
[102, 107]. Since PLTP contributes to the transport of the 
surface remnants after lipolysis of triglyceride rich food and 
ultimately helps in generation of pre ?-HDL, it also contrib-
utes to lowering the atherosclerotic burden [102, 107]. Simi-
larly enzymes like lipoprotein lipase (LPL) and hepatic li-
pase (HL) also contribute to generating pre ?-HDL [102, 
107]. HL facilitates the conversion of triglyceride rich HDL 
particles (HDL2) to HDL3 [102, 107]. Regulation of HL and 
PLTP is crucial in RCT [102, 107]. The protein CETP which 
is secreted by liver, binds to HDL and brings about the trans-
fer of cholesterol ester from HDL to very low density lipo-
protein (VLDL) and LDL and in turn transfers triglyceride 
from the latter to HDL [102, 107]. Cholesterol esters can 
thus be removed from the liver by low density lipoprotein 
receptor (LDLR) [102, 107]. This calls for an anti-
atherogenic effect of CETP. However, at the same time since 
it is leading to an increase in LDL-cholesterol, a decrease in 
HDL-cholesterol may lead to proatherogenic events [102, 
107]. Therefore, caution is to be observed when targeting 
this molecule for atherosclerosis treatment. These aspects 
should also be looked into while evaluating the failure of 
CETP inhibitor, torcetrapib [102, 107].  
 Atherosclerosis is now considered an inflammatory dis-
order and inflammation is being considered as an attractive 
therapeutic target [59, 60]. One of the major challenges is to 
connect dyslipidemia with the increased inflammation ob-
served during atherosclerosis [59, 60]. Toll like receptors 
(TLR) are a class of pattern recognition receptors, which 
besides taking part in inflammatory response also regulate 
cell survival and cell death of lesion macrophages [6, 109-
111]. Thus, they regulate the development of the lipid rich 
necrotic core. Nuclear receptors on the other hand play a 
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dual role in atherosclerosis by mediating changes in both 
inflammatory and lipid pathways [6, 112-116]. The anti-
inflammatory effect of liver X receptor (LXR) and PPAR? 
ligands is mediated by trans repression of inflammatory tar-
gets genes like TLR and NFkB [6, 112, 113, 116, 117]. 
However, these receptors also regulate fatty acid metabolism 
in a number of ways and may affect the process of athero-
sclerosis in several ways [6, 112, 113, 116, 117]. The prob-
lem with classical LXRs is that beside their protective anti-
inflammatory effect their activation also leads to the increase 
in fatty acid and triglyceride synthesis [118-124]. Since nu-
clear receptors like LXR and PPAR heterodimerize with the 
retinoid receptors leading to their activation, retinoid recep-
tors can also be targeted in atherosclerosis [125-127]. A 
more recent approach is to exploit the process of transrepres-
sion in case of nuclear receptors [112, 113, 116, 117]. In case 
of novel specific PPAR? and dual PPAR?/? agonists, safety 
concerns have led to their discontinuation in clinical trials 
[128]. These include associated carcinogenecity observed in 
rodents, signs of myopathy and rhabdomyolysis, increase in 
plasma creatinine and homocysteine, weight gain, fluid re-
tention, peripheral edema and potential increased risk of car-
diac failure [128]. The toxicological side effects observed are 
believed to be very compound specific [128].  
 Macrophages presents entitities like chlamydia pneu-
miniae, herpes simplex, cytomegalovirus, heliobacter pylori, 
and lipid derived immunogenic neo epitopes to T cells in the 
atherosclerotic plaques to start a series of immunological 
events [129]. The type of cytokine, growth factor and other 
cytokines released as a result of these interactions, ultimately 
decide the fate and the type of inflammatory response [129]. 
The T cell releases both anti-inflammatory [IL-5, IL-10, 
transforming growth factor ? (TGF?)] and pro inflammatory 
cytokines (interferon gamma (IFN-?), IL-4) [129]. Which 
stimulus triggers which type of cytokine is the real challenge 
for researchers and if one could just increase the anti-
inflammatory response during atherogenesis then this may be 
beneficial therapy wise. T cell activation also activates 
macrophages which in turn produce pro atherogenic media-
tors like proteases, show increased uptake of Ox-LDL, in-
creased TF expression, secretion of reactive oxygen species 
(ROS), reactive nitrogen species (RNS) and pro inflamma-
tory cytokines IL-1, IL-6 and TNF-? [129]. Secretion of 
various chemokines also amplifies leukocyte migration to the 
endothelium and regulate atherosclerosis progression [92]. 
Products released as a result of 15-LOX mediated arachi-
donic acid (AA) and linoleic acid (LA) acid oxidation, have 
been shown to be proinflammatory and prothrombotic [130, 
131]. 12/15-LOX can regulate the expression of key proin-
flammatory, pro atherosclerotic T helper (Th)1 cytokine, IL-
12 [132]. Phospholipase A2 (PLA2) activation also leads to 
the generation of lipid-derived inflammatory mediators in-
cluding platelet activating factor (PAF), AA and prosta-
glandins (PG), all contributing to the generation and amplifi-
cation of an inflammatory response [133, 134]. AA by the 
action of LOX and five lipoxygenase activating protein 
(FLAP) gets converted to leukotrienes, which play a role in 
inflammation and vasoconstriction thus increasing athero-
sclerotic load [135, 136]. They can be targeted for anti-
atherosclerotic therapy. Isoprostanes released as a result of 
non-enzymatic degradation (lipid per oxidation) of AA, act 
on thromboxane prostanoid (TP) receptor to promote platelet 
aggregation and smooth muscle contraction [137]. AA me-
tabolism in platelets due to COX-1 and thromboxane (TX) 
synthase leads to the generation of prostaglandin H2 (PGH2) 
and TXA2, respectively [137]. TXA2 acts on the TP receptor 
to promote platelet aggregation and smooth muscle contrac-
tion [137]. However, PGH2 generated from AA by the action 
of COX-1 and 2 in the endothelium gives rise to PGI2 by the 
action of PGI2 synthase [137]. PGI2 acts on the PGI2 recep-
tor (IP receptor) to inhibit platelet aggregation and smooth 
muscle relaxation [137]. A disturbance in the dynamic bal-
ance of the above two processes may lead to prothrombotic 
changes [137]. Antioxidants also block the generation of 
isoprostanes by inhibiting lipid peroxidation of AA [137]. 
 Cell proliferation in atherosclerosis leads to more com-
plex lesions and plays a fundamental role in plaque forma-
tion and rupture [98, 99, 138-142]. Macrophage and VSMC 
proliferation observed during this disorder prolongs their 
presence in the vessel wall and hence increases the chances 
of plaque formation and rupture [98, 99, 143, 144]. How-
ever, increase in macrophage content is associated with un-
stable plaque [98, 145], the increase in VSMC content [99, 
145] makes the plaque more stable due to the shielding of 
vessel contents from the outside environment [98, 99, 145]. 
However, VSMC proliferation observed after balloon an-
gioplasty and stent implantation leads to restenosis [58, 146, 
147]. Besides this vascular remodeling has also been said to 
be responsible for this [148, 149]. Matrix metalloproteinases 
(MMPs) also influence survival, proliferation and migration 
of VSMC [141]. VSMC apoptosis induces plaque vulnerabil-
ity and apoptosis [150]. mTOR inhibitor rapamycin, which 
inhibits VSMC proliferation, is in effective use in clinic and 
is applied on stents for preventing restenosis [146, 147, 151]. 
Defective removal of macrophages, their necrotic cell death, 
releases MMPs e.g. MMP3 which degrade the extracellular 
matrix and result into release of TF and activation of coagu-
lation cascade and thrombosis [152, 153]. 
ANIMAL MODELS OF ATHEROSCLEROSIS 
 A wide range of animals has been used to study athero-
sclerosis, as discussed below. 
Hamster 
 Golden Syrian hamster, preferentially F1B strain is used 
as model for studying hyperlipidemia and atherosclerosis. 
Hamsters have quite a few similarities with humans which 
makes them a valuable model of atherosclerosis. These fea-
tures include, LDL as the major circulating lipoprotein [154], 
similar cholesterol and bile acid metabolism [155], similar 
LDLR gene [156, 157] profound CETP activity[158], exclu-
sive hepatic production of ApoB100 [159], human like le-
sions Ca deposits and necrosis in lesions [160]. Hamsters are 
also sound responders to dietary manipulations with respect 
to plasma lipid levels and lipid metabolism [161]. They do 
show influence of other metabolic disorders on lipoprotein 
metabolism [162, 163], and can develop extensive hyper-
triglyceridemia [154]. APA strain Syrian hamsters show 
signs of hypercholesterolemia, hypertriglyceridemia and 
atherosclerotic lesions under diabetic condition induced by 
streptozotocin (STZ) and thus is a good model to study athe-
rosclerosis along with its complications [164, 165]. Hamsters 
develop diabetognic atherosclerosis characterized
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by accelerated atherosclerotic plaque formation and vascular 
dysfunction in diabetic environment, thus providing a model 
to evaluate the anti-atherogenic effect of hypolipidemic 
drugs and antioxidants [163, 166]. Hamsters also respond to 
inflammatory regulations in atherosclerosis, and studies have 
shown changes in SRB1 expression, apolipoprotein levels 
and lipid metabolism after infection (endotoxin) and/or in-
flammatory stimulation [167-169]. Hamsters also show diet 
specific change in cytokines (TNF-?, IL-1?, IL-1?, IL-6) 
production [170]. Since this model responds well to dietary 
modifications, it is excellent for studying diet-induced 
plasma lipid levels and effect of hypolipidemic agents. Simi-
larity with the human LDLR gene, make it ideal to study 
LDLR antagonists and also useful for drugs which interfere 
with CETP activities and RCT [171]. Hamsters can also be 
used to evaluate candidate drugs affecting the inflammatory 
pathway, since they do show signs of inflammation as men-
tioned above. However, the major limitations include lack of 
spontaneity in lesion formation and absence of advanced 
atherosclerotic lesions and plaque rupture. Furthermore, 
platelets are much less sensitive towards hyperlipidemia in 
this species [172].  
Guinea Pig 
 This is a useful model of dyslipidemia and to investigate 
hypocholesterolemic drugs [173]. Their human-like features 
include, RCT components e.g. CETP [174], LCAT [175], 
LPL [176], majority of circulating cholesterol as LDL [177] 
and moderate rates of hepatic cholesterol synthesis [177] and 
catabolism [178]. They respond well to dietary cholesterol 
[179], fibres [178] and saturated fat [180]. Mechanism of 
apical sodium dependent bile acid transporter (ASBT) inhibi-
tors [181], statins [182] and drugs interfering with triglyceri-
des metabolism can also be explored [183,184]. Guinea pig 
models also exhibit elevated level of atherosclerosis linked 
inflammatory components (IFN-?, TNF-?, IL-1?, IL-8, and 
MCP-1) in diet-induced atherosclerosis [185]. A study 
showed that polymorphonuclear leukocytes (PMN) obtained 
from hyperlipidemic guinea pigs are associated with an 
augmented generation of ROS by increasing the expression 
of protein kinase C (PKC) alpha, betaI and gp91phox and 
pitavastatin has an inhibitory effect [186]. Ovariectomized 
guinea pigs have a plasma lipid profile similar to post-
menopausal women [187]. High plasma Lp(a) is associated 
with coronary heart disease and other forms of atherosclero-
sis in humans, and the presence of Lp(a) in guinea pigs 
[188], makes them useful to assess the role of this lipoprotein 
in atherosclerosis. Guinea pigs are a model for dietary inter-
ventions and provide an opportunity to study the influence of 
gender and hormones on lipid metabolism [187]. The major 
limitation of this model is the requirement of vitamin C 
[189] as dietary supplement, which has antioxidant activity 
and may interfere in atherosclerosis development [190]. 
They do not develop advanced atherosclerotic lesions, and 
are not a well-established model for atherosclerosis progres-
sion [190]. 
Rabbit 
 Rabbits are the most frequently studied animal model for 
spontaneous [191, 192] as well as diet-induced atherosclero-
sis [193]. New Zealand White (NZW) rabbits are the strain 
commonly used [194]. Although they have low plasma total 
cholesterol concentrations and HDL as dominant lipoprotein 
[195], ?VLDL becomes the major class of plasma lipopro-
teins when exposed to cholesterol rich diet [196-198]. In 
conjunction with chylomicron remnants ?VLDL becomes 
highly atherogenic [199]. Besides the presence of pro-
nounced CETP activity [200, 201], these animals show hu-
man-like Apo B [202], low HL activity [203] but lack an 
analogue of human Apo A-II [202, 204]. The NZW rabbit 
rarely shows spontaneous lesions [11] and on feeding with 
diet rich in saturated fat and cholesterol they form lesions 
rich in foam cells with some fibrous component in the as-
cending aorta and aortic arch along with xanthomatosis 
[205]. The Watanabe heritable hyperlipidemic rabbit devel-
ops spontaneous hypercholesterolemia [206, 207], has high 
plasma LDL, fibrous lesions which are rich in foam cells 
[208] and develop spontaneous myocardial infarction [209]. 
St. Thomas’ Hospital strains manifests endogenous hyper-
cholesterolemia and hypertriglyceridemia, and develops 
atherosclerosis with certain features closely resembling hu-
man disease [210, 211]. Availability of transgenic models 
such as human ApoE2 and Apo (a) rabbits [212, 213] pro-
vide a basis to understand disease progression and its corre-
lation with the lipid environment and associated complica-
tions such as plaque rupture and aneurysm formation [127]. 
The expression of various inflammatory mediators IL-1?, 
MCP-1, 5LOX, PGE2 [214, 215], COX-2 [216, 217], 
VCAM-1 [218], have been studied in this model and are said 
to be responsible for plaque formation and rupture. Lipid 
lowering in rabbit reduces TF expression, proteolytic and 
prothrombotic potential [219, 220]. Increased platelet aggre-
gation have been found in hyperlipidemic rabbits [172]. This 
model has been used in restenosis studies arising as a result 
of balloon angioplasty [221, 222]. 
 Low HL activity, and lack of an analogue of human Apo 
A-II, provides a unique system to assess the effects of these 
human transgenes on plasma lipoproteins and atherosclerosis 
susceptibility [223]. Due to their large size, imaging tech-
niques such as ultrasound computed tomography and mag-
netic resonance imaging can be effectively applied to deter-
mine the plaque composition, distribution pattern, and some-
how its vulnerability [224]. This model is also suited to 
study the effect of atherosclerosis associated complications 
such as hypertension [225] and diabetes [226] on disease 
progression. Since this model does not produce spontaneous 
plaque rupture, various manipulations (balloon injury) have 
been applied to study various aspects of plaque rupture 
[227]. The rabbit model can be used to study the expression 
of adhesion molecules, and production of cytokines and 
other inflammatory mediators in the presence or absence of 
candidate drugs. Among the major drawback is the absence 
of important RCT component, HL [203], spontaneous athe-
rosclerosis is not observed and occurrence of cholesterol 
storage syndrome depends on high cholesterol feeding. At 
the same time the formed lesions are more fatty and macro-
phage rich than human and also differ in location [228]. 
Rabbits are not an effective model for drugs having activity 
on HL and Apo A-II [203, 204].  
Mouse 
 Naturally mice are resistant to atherosclerosis progression 
[229], but due to the availability of an atherosclerosis sus-
ceptible strain and provision for generating knockout/trans- 
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genic lines, they are sought after models [230, 231]. Ad-
vanced genetic manipulations in this model have helped in 
generating information regarding atherosclerosis initiation, 
progression, advanced plaque formation and rupture [232]. 
The genetically engineered mice lacking genes involved in 
lipid transportation, metabolism help to elaborate their role 
in atherosclerosis and other cardiovascular disorders [229]. 
One susceptible strain C57BL/6 got major attention from 
researchers for atherosclerosis progression [233] and princi-
pally for generating knockout/transgenic lines. Many trans-
genic mice like ApoC-III [234, 235], ApoE3 Leiden [236, 
237], CETP [230], sPLA2 [238, 239], ApoB100 [240], 
CETP- ApoB100 [240], LDLR-/- ApoB100 [241], hApoM 
transgenic [242] have been created and are useful in unders-
tanding the mechanism of the disease and candidate drug 
molecules. The major limitation with transgenic models is 
the non-physiological high expression levels, which may not 
be similar to humans. Knockout models like ApoE-/- [231, 
243-247] and LDLR-/- [231, 247-250] have great utility in 
deciphering the molecular events of atherosclerosis and 
screening candidate drugs for anti-atherosclerotic effect. 
Mice models are well characterized for various aspects of 
disease progression like macrophage foam cell formation, 
the involvement inflammatory mediators [251-256], cell 
adhesion molecules [257, 258], smooth muscle cell prolifera-
tion [259], apoptosis [260] nitric oxide synthase regulation 
[261], endothelial function impairment and NO production 
[262-264]. Plaque rupture is also seen in ApoE -/- mice es-
pecially when exposed to western type diet [265]. These 
models can also be used to study atherosclerosis progression 
along with diabetes [9, 266] and obesity [267]. Since mice 
are well characterized and researcher friendly, they are 
strong tools to characterize the progression of atherosclerosis 
and study the involvement of various inflammatory media-
tors. With the help of transgenic and knockout lines, the role 
of various signaling proteins in atherosclerosis progression 
can be easily studied. Diabetes and hypertension both have a 
synergistic effect on atherosclerosis development in the 
mouse model and thus offers a tool to study the combination 
of these metabolic disorders. Various approaches applied to 
develop hypertension in atherosclerosis prone species (such 
as deoxycortisone acetate salt induction, AngII administra-
tion) resulted in accelerated atherosclerosis [268]. Another 
finding suggests increased plaque necrosis and atherothrom-
botic vascular disease in insulin resistant syndromes [269].  
 Major disadvantages of mice are that they are highly re-
sistant to atherogenesis, need genetic manipulations and have 
high HDL. The RCT component CETP is absent [12] and 
there are difficulties in blood collection sampling and dissec-
tion of miniature vessels. Correlation with human popula-
tions is as yet unknown in some transgenic models [238]. 
Some knockout models need dietary modifications to de-
velop atherosclerosis [231]. The high cost of experiment and 
lesions not very much similar to human are another disad-
vantage [245]. The model is not valuable for studies assess-
ing dietary effects on lipoprotein metabolism [247]. Even 
genetically manipulated mice develop lesions very slowly 
with chow diet supplement and supplementation with high 
fat is necessary [250]. 
 
Swine 
 This animal has remarkable similarities of lesion distribu-
tion, pathogenesis, and morphology with humans [11]. These 
are commonly used for studying atherosclerosis and related 
complications [270, 271]. Lesions formed in swine are char-
acterized by necrotic cores, calcification, neovascularization, 
and intraplaque hemorrhage that closely mimic advanced 
human atherosclerosis [272, 273]. Porcine species can de-
velop atherosclerosis without cholesterol feeding [274]. On 
being fed a high cholesterol high fat diet swine show close 
resemblance with human lipid profile [275]. Familial hyper-
colesterolemic swine with elevated level of the Apo C-III, B, 
and E are also available [276]. This is an efficient model to 
study the exercise-induced changes in lipid metabolism [277] 
and to study vascular function [278]. Porcine platelet aggre-
gation resembles humans [279] thus making them useful for 
inducing atherothrombotic complications. Miniature pigs 
that are fed with high cholesterol, high fat, high sucrose diet 
show elevated expression levels of various cytokines 
(EOTAXIN-2, granulocyte colony stimulating factor (G-
CSF), ICAM, IFN-?, I-309, IL-1?, IL-1?, IL-6SR, IL-8, IL-
10, IL-11, IL-12P40, IL-12P70, IL-13, IL-15, IL-16, IL-17, 
IP-10, MCP-1, MCP-2, gamma interferon-induced monokine 
(MIG), macrophage inflammatory protein (MIP)-1?, TGF-?, 
TNF-?, TNF-?, regulated upon activation normal T-cell ex-
pressed and secreted (RANTES) and tumor necrosis factor 
receptor-I (sTNFRI) [280, 281]. VCAM-1, ICAM, IL-1?, IL-
1?, IL-6SR, MCP-1, MCP-2, TNF-?, TNF-?, were predomi-
nantly involved in the development of diabetes mellitus and 
atherosclerosis in this model [280, 281]. The effect of dietary 
cholesterol withdrawal on vascular inflammation, C reactive 
protein (CRP) level, and plaque stabilization has also been 
evaluated in miniature pigs [282]. Swine models can thus be 
effectively used to study the effect of drug/candidate mole-
cules on lipid metabolism, inflammation, lesion formation 
and plaque rupture. The swine model can be used to study 
atherosclerosis-associated hypertension [270] and diabetes 
[271]. Large size swine are the effective model to study ca-
rotid artery stent techniques [283], and invasive therapies for 
the treatment of atherosclerosis [284, 285]. Availability of 
miniature pigs is another advantage for studies where size is 
a problem. Major limitations include requirement of high 
cholesterol diet (4–5% w/w) to induce atherosclerosis and 
very low baseline cholesterol level [12]. Spontaneity in de-
velopment of metabolic syndrome and insulin resistance, is 
not common in this species [22, 286]. The difficulties in care 
and high maintenance cost has been overcome to some ex-
tent by the development of micropig and miniature swine 
[287, 288]. 
Avian 
 Avian species attracts many researchers by its ability to 
develop atherosclerosis spontaneously and/or diet induced 
[289-291]. Principally studied avian species include pigeon, 
chicken, Japanese quail, turkey [11] and parrots [292]. Pi-
geons got special attention due to relatively high plasma cho-
lesterol levels [293]. Although basal plasma HDL levels are 
on the higher side, ? VLDL and LDL become major lipid 
carriers when these animals are fed cholesterol rich diet  
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[293, 294]. Pigeons show similarity to humans in lipid me-
tabolism and lesion progression [12]. Avians are susceptible 
to both spontaneous and diet-induced atherosclerosis [295]. 
Pigeons also have resemble humans in increased platelet 
adherence, thrombosis, and impaired vascular smooth cell 
and endothelial function [12, 296, 297]. Platelet factor-4 
activation, elevation in thrombocyte adhesiveness, endothe-
lial damage and sterol accumulations are the earliest events 
in the pathogenesis of spontaneous pigeon atherosclerosis 
[296-298]. White Carneau (WC) strain develops spontaneous 
atherosclerosis with defined lesions [12]. WC pigeon aortic 
smooth muscle cells (SMCs) lack a functional LDLR path-
way and in this way resemble cells from human beings with 
homozygous familial hypercholesterolemia or from Wata-
nabe rabbits [299]. Monocyte chemoattractants have also 
been analyzed in cholesterol fed WC pigeons [300]. 
 African Grey and Amazon parrots are susceptible to athe-
rosclerosis [211, 301, 302]. Risk factors to develop athero-
sclerosis include elevated cholesterol level, diet composition 
[301, 302], social stress and inactivity [292]. Parrots also 
show increased platelet aggregability and elevated plasma 
cholesterol level [301, 302] and polyunsaturated fatty acids 
ameliorate severe atherosclerosis in these birds [301, 302]. 
Limitations in parrots include, less information [292] and 
clinical signs are seldom seen [292]. In general, avians are 
non-mammalian and mechanism wise atherosclerosis is not 
well characterized. HDL is the major circulating lipoprotein. 
There is lack of Apo E [303], B48 [12], and chylomicron 
formation [12] as well as a large variation in time (12-16 
weeks to 9-27 months [304-309] and cholesterol amount 
(0.5-5%) needed to develop atherosclerosis [304, 305, 310]. 
Dog 
 This species do not develop spontaneous atherosclerosis 
[11]. Besides dietary supplement rich in cholesterol and satu-
rated fat, thyroid suppression is also required for atheroscle-
rosis development [11]. On cholesterol rich diet treatment 
animals develop lesions throughout the arterial tree and 
coronary vessels accompanied with prominent vascular 
changes [311, 312]. Beagles show useful similarities with 
human in cholesterol synthesis, and lipoproteins level [313] 
and this model has been successfully used to demonstrate the 
effect of statins on cholesterol synthesis [313, 314]. Dogs 
treated with colestipol (a bile acid sequestrant) and mevino-
lin (a cholesterol synthesis inhibitor) produced a 3-fold in-
crease in LDL binding activity on liver membrane [315]. The 
role of vascular NAD(P)H oxidase-derived superoxide anion 
(O
2-
) in endothelial dysfunction in dogs with tachycardia-
induced congestive heart failure (CHF) and the therapeutic 
effect of statins [316], the effect of antioxidant in hyperlipi-
demic dogs [317] has been studied. Miniature Schnauzer 
dogs have been used in various studies involving analysis of 
solid intraocular xanthogranuloma formation [318] and the 
prevalence and severity of hypertriglyceridemia with age 
[319]. Since this model has close resemblance with humans 
in cholesterol synthesis and lipoprotein level, it can be useful 
to screen HMG CoA reductase inhibitors. Due to size, dogs 
are imaging friendly. In addition, this model can be of good 
predictive value regarding hypocholesterolemic effect on 
disease progression in humans [313, 315, 320, 321]. Hy-
potensive, anti-atherogenic and coronary dilating effect of 
plant extracts has been evaluated in dogs [322]. A study con-
ducted to find out the association between diabetes mellitus, 
hypothyroidism and atherosclerosis in dog, showed that dia-
betes mellitus and hypothyroidism are more prevalent in 
dogs with atherosclerosis compared to dogs without athero-
sclerosis on postmortem examination [323]. 
 A study conducted on mongrel dogs showed that IL-10 
has protective effect on cerebrovascular dysfunction induced 
by inflammation and significantly depressed adherence of 
monocytes to cerebrovascular endothelial cells and inhibited 
up-regulation of ICAM-1 and VCAM-1 [324]. Due to their 
large size, they can be easily applied to in vivo detection of 
vulnerable plaques [325] and other invasive techniques. Ma-
jor limitations are absence of natural atherosclerosis devel-
opment, poor response to dietary cholesterol [12] not well-
characterized, large amount of experimental agents needed 
and ethical issues. 
Rat 
 Generally rats are highly resistant to the development of 
atherosclerosis [22]. HDL is dominating lipoprotein in these 
animals. Sprague-Dawley rats develop hyperlipidemia by 
triton administration [326]. Lymphatic cholesterol transport 
system [327] and the rate of hepatic secretion of VLDL in 
triton-induced hyperlipidemic rat [328] has been explored. 
Corpulent rats strain developed by cross between Sprague–
Dawley rats and spontaneously hypertensive rats (SHR) are 
hypertensive, obese, hyperlipidemic and hyperinsulinemic 
[22, 329, 330]. Advanced atherosclerotic lesions, reflecting 
aortic aneurysms are also observed [329, 330]. Another 
strain JCR:LA-cp is prone to atherosclerosis development 
and insulin resistance [331]. The cp/cp male phenotype de-
velops extensive atherosclerotic lesions [332-334], displays 
increased activity of PAI-1, vascular dysfunction [335] char-
acterized by impaired NO production and metabolism [22]. 
The CETP transgenic Fisher rat, shows large increase in non-
HDL lipid when fed with high-sucrose diet with implications 
for RCT and atherosclerosis [336]. Increased expression of 
the inflammatory cytokines (TNF?, IL-1?, IL-8 and VCAM-
1) and augmented foam cell formation found in chronic in-
fection induced by chlamydia pneumoniae [337] in white-
rats (Rattus norvegicus). The role of P-selectin in vascular 
inflammatory processes, has been evaluated in balloon in-
jured rat carotid arteries [338]. Rats are potentially useful 
model for studying hypercholesterolemia along with hyper-
tension. They exhibit augmented thrombotic response and 
develop coronary atherosclerotic lesions under hypertensive 
and hyperlipidemic conditions [339-341]. Elevated plasma 
cholesterol level and coagulation factors shows good correla-
tion in these animals [342]. They can be good model for an-
gioplasty restenosis [285]. Rats lack physiological resem-
blance on many aspects with humans that are pathophysi-
ologically important [285]. Rat platelets are generally resis-
tant in hyperlipidemic condition [172].  
 Sand rat (Psammomomys obesus), naturally become 
obese, insulin resistant and develop VLDL hyperlipidemia 
with energy rich (chow) diet [343-345, 22] and correlates 
with human type2 diabetes mellitus [22]. This can be an ef-
fective model to study the nature of hyperlipidemia and vas-
cular reactivity in the insulin resistant state [346-348]; espe-
cially type 2 diabetes mellitus [347].  
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Non-Human Primate 
 Non-human primates (NHPs) are an excellent model to 
study cardiovascular disease plus metabolic syndrome [22], 
since they are phylogenetically close to humans, eat a similar 
omnivorous diet, have similar metabolism, and develop both 
metabolic syndrome and cardiovascular disease (CVD) as 
they age [349, 350]. Commonly used models are Macaques 
species (stumptail, rhesus, cynomolgous, and the pigtail), 
Squirrel monkey, green monkey and African baboon [11]. 
They develop spontaneous (in some species) and high fat 
high cholesterol diet-induced lesions [351]. Lesions are simi-
lar to those in humans and show plaque mineralization and 
calcification [352, 353]. Hypertension in these models shows 
deleterious effect on atherosclerosis development [354], thus 
they are extensively used to study the effects of hypertension 
on atherosclerosis [351, 354, 355]. African green monkey 
and other primates have been used to study the effects of oral 
contraceptives on plasma cholesterol [11, 356, 357]. The 
close resemblance of plasma lipoprotein-lipid level, plaque 
development and its calcification and mineralization with 
humans makes them an excellent model to study the correla-
tion between plasma lipids and plaque development. The 
effect of the caloric restrictions on atherosclerosis develop-
ment has also been evaluated in the rhesus monkey [358]. 
Squirrel and rhesus monkeys exhibit augmented (mild) plate-
let aggregation in hyperlipidemic condition [172]. NHPs can 
also be used to study atherosclerosis along with diabetes-
hyperinsulinemia [359]. Macaca nigra is very valuable in 
studies focused on the interactions between atherosclerosis 
and diabetes [360]. Interactions between atherosclerosis and 
hypertension can also be studied effectively in NHPs [360]. 
Monkeys show good correlation between the levels of many 
coagulation factors and serum cholesterol [342], that may 
play role in atherogenesis. Lp(a) in conjunction with proin-
flammatory oxidized
 
phospholipids act in atherosclerosis, 
coronary artery disease and cardiovascular events [361, 362]. 
Lp(a) is also potentially involved in atherosclerosis plus 
thrombogenesis [363-365]. The presence of Lp(a) in NHPs 
(particularly in rhesus monkeys and baboons) resembling 
that in humans [366, 367] represents a good model for the 
study of the structure and biology of Lp(a) and its involve-
ment in atherosclerosis [368]. The major limitations include 
variations in site of lesions, expensive, difficult to house and 
handle, limited availability and ethical concerns.  
Lower Organisms 
 Lower organisms like worms (Caenorhabditis elegans), 
fly (Drosophila melanogaster) and zebrafish (Danio rerio) 
are good tools to study metabolic disorders and atherosclero-
sis and past research has helped in the elucidation of genetic 
and biochemical background of metabolic disorders such as 
obesity diabetes and atherosclerosis [13, 369-371]. The insu-
lin and insulin-like growth factor signaling pathway has been 
characterized in great detail in Drosophila and C. elegans 
[13]. ApoB (AI964937) is the main beta lipoprotein in ze-
brafish and whole animal protein levels are up-regulated in 
response to high fat feeding [13, 372]. As a vertebrate, ze-
brafish possesses many structural similarities with humans 
[372]. These animals are lab friendly and can be manipulated 
genetically. Easy genetic manipulation in lower organisms 
and the availability of genetically manipulated variants like 
mutant flies can deliver valuable information just like in 
mice [13, 373]. Caenorhabditis elegans and Drosophila 
melanogaster being invertebrates, have less similarity with 
humans. 
CELL BASED MODELS 
 A wide range of cells participate in the process of athero-
sclerosis and can be used to study atherosclerosis progres-
sion and the effect of candidate anti-atherosclerotic com-
pounds. 
Macrophages 
 The recruitment of monocytes/macrophages to the arte-
rial wall is an initiating event leading to atherosclerosis pro-
gression. This process is facilitated by the expression of en-
dothelial adhesion molecules namely, ICAM [374-376] 
VCAM [374, 377-379] endothelial-leukocyte adhesion 
molecule (ELAM), as well as P and E selectins. The conver-
sion of macrophages to foam cells by the accumulation of 
modified LDL, especially acetylated low density lipoprotein 
(AcLDL) and Ox-LDL, is another critical step in atheroscle-
rosis development [380-382]. Since monocytes differentiate 
(MCSF, GMCSF, Ox-LDL) [383], proliferate (Ox-LDL,) 
[6,383] and die (Ox-LDL) [383], during the process of athe-
rosclerosis, they can be tested on these aspects for the anti-
atherosclerotic effect of candidate drugs. Macrophage infil-
tration, LOX-1 and MCP-1 are reduced by chronic HMG-
CoA reductase inhibition by simvastatin (20 mg/kg) in 
common carotid artery of stroke-prone spontaneous hyper-
tensive rats (SHR-SP) [384]. Olmesartan and pravastatin 
additively reduce the development of atherosclerosis in 
ApoE3 Leiden transgenic mice [236]. Atorvastatin inhibits 
macrophage accumulation of oxidized lipids by inhibiting 
endothelial and LPL expressed in human acute monocytic 
leukemia cell line, THP-1 macrophages [385]. Similar results 
have been obtained with simvastatin [386]. Fibrates have 
also been shown to inhibit cholesterol esterification in 
macrophages [387]. Inhibitory effects of fluvastatin on cyto-
kine and chemokine production by peripheral blood mono-
nuclear cells has been observed [388]. Any test compound 
can be evaluated in a similar way for its protective effect in 
atherosclerosis. 
T Lymphocytes 
 The presence of activated T lymphocytes (principally 
CD4+ cells) in all stages of atherosclerotic lesion, give a 
potential clue for their participation in this disease [389]. The 
complete absence of lymphocytes reduces lesion formation 
in hypercholesterolemic condition [390, 391], which reveals 
their active participation [392]. The Th1 cell attracted atten-
tion regarding atherosclerosis progression because of the 
presence of its potential inducer IFN-?, and IL-12 in lesions. 
Various reports suggest that Th1 cells are atherogenic [393, 
394] whereas Th2 cells are atheroprotective [129, 395, 396]. 
One recent finding showed activation of LXR? and ? on 
CD4 positive lymphocytes which reduces Th-1 cytokine 
expression in these cells [397]. The CD40-CD40L system in 
conjunction with T lymphocyte mediates various inflamma-
tory responses in atherosclerosis [398]. The atherogenic 
(Th1), and atheroprotective (Th2) involvement of T lympho-
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cytes in atherosclerosis are a valuable tool to study the cyto-
kine regulated inflammatory pathways in atherosclerosis. 
Statins have an inhibitory effect on T cell activation [399, 
400]. Production of inflammatory (IFN-?,IL-12,IL-18,IL-4, 
TNF?) and anti-inflammatory (IL-10, TGF?,IL-5) cytokines 
in the presence of modified lipids, and in co-cultures with 
macrophages, VSMC in the presence of test compounds can 
be used to screen potential candidate drugs [401]. 
 Lovastatin inhibits T-cell antigen receptor signaling 
[402]. Statins also decrease T cell activation, the recruitment 
of monocytes and T cells into the arterial wall, and enhance 
the stability of atherosclerotic lesions [403]. Beneficial ef-
fects of anti-diabetic PPAR activators on atherosclerotic 
plaque development may be partly explained by their repres-
sion of MHC-II expression and subsequent inhibition of T-
lymphocyte activation [404]. 
Natural Killer T (NKT) Cells 
 NKT cells are a specific type of lymphocytes that play 
protective role in many autoimmune disorders [405]. Their 
immune responses are mainly mediated via up regulation of 
Th2 (principally) and Th1 cells [406-408], suggesting their 
role in atherosclerosis development [405, 409]. The presence 
of CD1d-expressing cells in human atherosclerotic plaques 
suggest NKT cells presence in lesions [410]. This has been 
well characterized in lipopolysaccharide treated ApoE-/- 
mice [243, 411]. A significant reduction in atherosclerotic 
lesion in NKT cell–deficient CD1d-/-
 
mice and in CD1d-/- - 
LDLR-/- mice has been reported when exposed to athero-
genic diet [412]. Lovastatin, has been shown to inhibit mito-
gen-stimulated proliferation of natural killer cells in vitro 
[413] and test compounds can be screened in a similar way 
for their effect in atherosclerosis.  
Vascular Smooth Muscle Cells 
 VSMCs synthesize fibrous protein (collagen) elastin and 
proteoglycans that provide extra strength to arteries. The 
death of SMCs in core of atherosclerotic plaques is critical to 
the weakening of plaque and its rupture. The migration of 
SMCs from media to intima and its cross talk with foam 
cells, Th cells, and cytokines (such as IFN-?, IL-10) compli-
cates atherosclerosis progression [5]. Human pulmonary 
artery smooth muscle cells (PASMC) can be used to assess 
the effect of inflammatory mediators on the expression of 
vascular adhesion molecules [414] and thoracic aorta derived 
SMCs are used to define the PDGF survival signals on vas-
cular smooth cells [415]. In the presence of statins VSMCs 
decrease their binding affinity for LDL [416]. Statins also 
reduce the proinflammatory activation of human VSMCs 
[417]. The protective effect of N-3 PUFAs in atherosclerosis 
has been attributed to their ability to modulate VSMC prolif-
eration, migration, and apoptosis [418]. Candidate drugs or 
test compounds can be evaluated in a similar way for their 
anti-atherosclerotic effect.  
Endothelial Cells 
 Endothelial cells are unique. They prevent clot formation 
and act as barrier between circulating blood component and 
underlying tissue components. The interaction of circulating  
 
monocytes and expression of adhesion molecules on vascular 
endothelial cells are the initiating events of atherosclerosis 
and is an attractive target [5]. Endothelial-dependent relaxa-
tion is hampered in atherosclerosis due to impaired NO 
bioavailability produced from endothelial nitric oxide syn-
thase (eNOS), which is important for vascular homeostasis 
and has anti-atherogenic action [419, 420]. This can be 
evaluated in a simple organ bath system [421]. Human um-
bilical vein endothelial cells (HUVEC) are used to define the 
role of various surviving factors such as hepatocyte growth 
factor, NF-?B in atherosclerosis [422] and to explore the 
involved signaling event [423]. Recently HUVEC was used 
to explore the anti-inflammatory effect of aspirin in presence 
of oxidized LDL [424]. Endothelial progenitor cells (EPCs) 
attracted special attention because of their ability to repair 
endothelium and initiate neovascularization. Circulating 
EPCs are markers for cardiovascular risks [425]. EPCs have 
also been proposed as heredity markers of atherosclerosis 
susceptibility [426]. Since endothelial cells secrete prothrom-
botic, anti-thrombotic and thrombolytic agents, they can be 
set up for evaluation of such activities in the presence and 
absence of test compounds [96, 427]. Simvastatin exerts a 
protective effect by regulating the chemokines and 
chemokine receptors on endothelial cells [428]. Fluvastatin 
exerts a protective effect on the endothelium through lipid-
lowering independent effects [429, 430]. Rosuvastatin in-
creases vascular endothelial PPAR? expression and corrects 
blood pressure variability in obese dyslipidaemic mice [431]. 
Adverse balance of NO/peroxynitrite in the dysfunctional 
endothelium can be reversed by statins [432]. Fluvastatin 
inhibits up-regulation of TF expression by anti-phospholipid 
antibodies on endothelial cells [433]. 
Adipocytes 
 Various experimental findings indicate that adipocytes 
act as a source of hormones and endocrine molecules known 
as adipokines [434], many of which have a potential role in 
atherosclerosis [435]. Adipocytes also have a potential role 
in cholesterol homeostasis [435]. Adiponectin has anti-
inflammatory and atheroprotective properties [436]. Its 
plasma levels are low in obese individuals and weight loss 
restores levels [437]. Another adipokine, leptin, has athero-
genic and thrombotic properties [435, 438]. The leptin recep-
tor has been confirmed on human atherosclerotic lesions and 
its role has been explored regarding atherosclerosis and 
thrombosis in mice models [439, 440]. Leptin and adipocy-
tokines seem to bridge the gap between immunity and athe-
rosclerosis [441]. Adipocytes can be set up in presence and 
absence of candidate anti-atherosclerotic drugs for the secre-
tion of such adipokines, which can be estimated by conven-
tional methods [441-444]. Atorvastatin reduces TF expres-
sion in adipose tissue of atherosclerotic rabbits [445]. 
Atorvastatin also reduces PAI-1 expression in adipose tissue 
of atherosclerotic rabbits [446]. Atorvastatin can inhibit IL-6 
secretion in adipocytes possibly through upregulating 
PPAR?, which may help to explain the anti-inflammatory 
effects of statins [447]. Adipocyte LPL expression is also 
induced after statin treatment [97]. Assays using the above 
parameters can be set up in the presence and absence of test 
compounds. 
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Hepatocytes 
 In mammals, hepatocytes play a key role in the whole 
body cholesterol homeostasis by fine tuning of plasma lipo-
protein concentrations and cholesterol synthesis, relocation, 
and regulation [448]. HL, ACAT2, LDLR, CETP, ApoA-I, 
ApoE, SRB1, LXR are the principal components of hepatic 
cells which regulate cholesterol homeostasis. A recent find-
ing indicates the role of nuclear receptors [LXR, and hepato-
cyte nuclear factor-4?, (HFN-4?)] in cholesterol efflux 
pathway [449]. Bile acids synthesized in liver, are key play-
ers in lipid absorption and excretion [450-452]. Hepatocytes 
can be used for lipid uptake studies and clearance from the 
body, lipid metabolism, lipid transportation, and cholesterol 
synthesis [453-459]. Fibrates down-regulate hepatic SRBI 
protein expression in mice and thus inhibit atherosclerosis 
progression [460]. The anti-inflammatory activities of 
PPAR? activators and statins have been explored in hepato-
cytes [461]. It is believed that by preventing the reabsorption 
of bile acids, a minimally absorbed ASBT inhibitor would 
lower serum cholesterol without the potential systemic side 
effects of an absorbed drug [462]. A series of novel ben-
zothiepines   (3R,3R'-2,3,4,5-tetrahydro-5-aryl-1-benzothie-
pin-4-ol 1,1-dioxides) were synthesized and tested for their 
ability to inhibit the ASBT-mediated uptake of [
14
C] tauro-
cholate (TC) in H14 cells [462]. A transfected baby hamster 
kidney cell line (H-14) that constitutively expresses human 
ASBT can be used [463]. ASBT inhibitory activity is as-
sessed on the basis of the ability of compounds to inhibit the 
cellular uptake of 5 μM [14C]taurocholate during a 2 h incu-
bation. Selectivity is tested in the same assay system using 5 
μM [14C]alanine instead of taurocholate to determine the 
effect on another cellular sodium-dependent cotransporter 
[462]. Hepatocytes can be tested for hypolipidemic effect by 
incubating them in presence or absence of test compound or 
statin and estimating the VLDL levels (measured by Apo 
B100) in HepG2 cells [464].  
Mast Cells 
 Mast cells are involved in allergic and innate immune 
response and recent studies reported their presence in human 
atherosclerotic lesion [465]. Various in vitro - in vivo studies 
have shown their active participation in atherogenesis [466] 
by releasing proteases (interfere with arterial remodeling) 
[467], cytokines (activate vascular cells) [468], and 
chemokines (attract leukocytes) [469]. With the help of vari-
ous inflammatory mediators released from mast cells these 
cells can be involved in atherogenesis [470, 471]. Few re-
ports suggest the participation of mast cells in the genesis of 
vulnerable plaques [472, 473]. These cells can be set up in 
the presence of various candidate drugs and secretions of 
various mediators can be monitored by conventional meth-
ods. Mast cell accumulation has also been reported at the site 
of deep venous thrombosis, liver vein thrombosis and pul-
monary embolism [474-476]. The inhibitory effect of statins 
on the growth and function of human mast cells and may be 
one of the beneficial pleiotropic effects of statins [477]. 
Dendritic Cells 
 Dendritic cells (DCs) are specialized antigen-presenting 
cells which initiate the primary immune response by the ac-
tivation of T-lymphocytes [478]. The presence of DCs in 
early [479-481] as well as in advanced [482] atherosclerotic 
lesions potentially indicates their involvement in atheroscle-
rosis progression. Endothelial dysfunction in atherosclerosis, 
regulates the DC adhesion and migration [483]. In vitro ex-
periments show an increase in migration of DCs when endo-
thelial cells are exposed to atherogenic conditions [483]. The 
presence of activated DCs alone or as cluster with T cells in 
atherosclerotic and rupture prone regions indicate their im-
portance in atherogenesis and plaque rupture [482, 484, 485]. 
As majority of them are present in rupture prone areas of 
advanced plaques, DCs can be a useful marker for plaque 
vulnerability and any candidate drugs decreasing their popu-
lation can stabilize plaques. Mature DCs express CD83 and 
they can be detected immunochemically in the lesions [486]. 
Besides this CD197, CD1a, CD4, CD8, CD80 are a few 
other markers of this cell [487, 488]. Maturation of DCs is 
suppressed by statins [489]. Preincubation of DCs with stat-
ins decreases their adhesion as well as recruitment to human 
microvascular endothelial cell line (HMEC-1) [490]. The 
immunomodulating effect of simvastatin on DCs is by fa-
vouring Th2 and inhibiting Th1 cell development [491]. 
Enterocytes 
 Enterocytes mediate the ingested and biliary cholesterol 
uptake and this serves as the rate limiting step in cholesterol 
absorption [492] and is a useful target for lipid-lowering 
approaches [493]. Ezetimibe, an inhibitor of intestinal cho-
lesterol absorption, acts at the brush border of the small in-
testine and inhibits the uptake of dietary and biliary choles-
terol into the enterocytes [494, 495]. Caco2 cells an intestinal 
cell line used in several studies to explore mechanistic aspect 
of dietary and biliary cholesterol uptake has been used to 
assess the efficacy of various inhibitors such as ezetimibe 
[494], SCH5803 [327], SC-435 (ASBT inhibitor) [463]. The 
effect of test compounds on lipoprotein production in Caco2 
human intestinal cells can be evaluated by incubating for 24h 
with test agent or 10 ?mol/L of atorvastatin. Chylomicron 
levels (measured by ApoB48) in Caco2 cells were measured 
using western blotting. Intracellular cholesterol levels can be 
measured using gas chromatography [464]. 
KINETIC MODEL 
 This model is based on the principle that a transition 
from one state to another, leading to a cardiovascular event 
obeys a simple exponential law [17]. This model keeps in 
mind the 2 concepts of atherosclerosis development [17]. 
Physical concept takes into account the magnitude of vascu-
lar stenosis causing functional cardiovascular ischemia [17, 
496] and the biochemical concept is based on the inflamma-
tory process associated with atherosclerosis progression and 
plaque rupture [17, 497]. According to the kinetic model, the 
normal, stenotic, inflammatory and event states can transi-
tion between each other [17]. The transition between the 
states is governed by rate constants, which in turn depend on 
many pathophysiological events taking place in atherosclero-
sis [17]. This model considers simultaneously the physics of 
anatomic stenosis and the chemistry of plaque instability for 
determining the dynamic processes that lead to atherosclero-
sis [17, 498, 499]. Kinetic data like time required for state-
to-state transition is required for this model to be exploited to 
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its full potential. However, some observational data is avail-
able on the basis of which the utility of this model has been 
checked [500-503]. An example of this model is develop-
ment of heart failure as the event state resulting from hyper-
tension or ischemia as the intermediary states [17]. The 
drawback of this model is that it fails to consider genetic and 
environmental factors such as insulin resistance [17, 504]. 
Some support for this kinetic model also comes from ex-
perimental findings [17, 505-507]. This model needs valida-
tion and is very preliminary but it tries to blend the laws of 
physics and chemistry with biology. 
ANALYTICAL MODEL 
 Importance of hemodynamics in atherosclerosis has been 
realized from the response to injury findings [508, 509]. 
Since atherosclerotic lesions are developed only in particular 
regions of the vessel wall, the structural aspects and fluidics 
become important aspects [510]. Atherosclerosis involves 
nanoscale fluid dynamics and macromoleculer transport at 
the arterial endothelium and thus the importance of thermo-
dynamics and shear stress is taken into account while pre-
dicting the probability of atherosclerosis progression [510].  
Thermodynamic Model 
 This model is based on the hemodynamic force exerted 
by the flowing blood on the endothelium [16]. This force 
affects the endothelium’s physical and biochemical proper-
ties leading to its dysfunction [16]. The probability of its 
formation depends on the kinetic and static energy of a le-
sion [16]. It is based on the principle that to form a lesion 
there is some minimal energy required. At the same time 
since the blood flow will follow the principles of conserva-
tion of energy, there will be some kinetic energy associated 
with lesions, which depends on the interfacial shear resis-
tance and the adhesive length over which the lesion is sup-
posed to form [16]. At the same time the energy that is 
needed for lesion formation (static energy) will depend on 
the work done by the axial transient inertial force ‘f’ to get 
deposited on the vessel [16]. If static energy is more than the 
dynamic/kinetic energy, LDL will get deposited on the endo-
thelium and in case of vice versa, it will keep flowing [16]. 
In such type of models factors like the rate at which blood 
flows, the stickiness of the endothelium will ultimately de-
termine whether the lesion will form or not [16]. 
Dynamic Boundary Value Model 
 This model is based on the fact that atherosclerotic le-
sions are usually located in regions of reduced shear stress of 
the fluid [511-518]. The shear stress is often associated with 
flow separation and turbulence [511-518]. Reduced shear 
stress leads to the formation of a transient boundary layer in 
atherosclerotic lesion forming regions [511-518]. Athero-
sclerotic lesion formation depends on the plasma viscous 
flow in the transient boundary layer near the inner tube wall 
at an arterial branch point [511-518]. The model takes into 
account the Navier-Stokes equation for deriving the prob-
ability of lesion formation [16]. Parameters like velocity 
vector of the fluid, body force vector, pressure vector and 
viscosity, density of fluid are important for lesion develop-
ment [16]. Factors like the axial velocity of the plasma fluid 
and the thickness of the transient boundary layer [16] may 
determine the ultimate outcome [16]. 
 On the basis of the above models it can be concluded that 
the probability and location of a lesion depends upon regions 
of increased transient boundary layer and reduced surface 
energy of adhesion which answers why lesions are formed 
only in small regions of the entire vascular system [16]. Ar-
terial branch points due to their structure tend to have an 
increased eddy velocity of the fluid and reduced viscous 
shear stress. This is responsible for reduced surface energy 
of adhesion, which brings LDL from the plasma fluid to the 
plasma – endothelial interface resulting in lesion formation. 
Although this model finds support in the literature [16], it 
needs more validation. 
QTL ANALYSIS 
 QTL linkage analysis is aimed to find correlations be-
tween genotype and phenotypes by crossing inbred mice 
strains and using specific QTL softwares and identify genes 
contributing to the polygenic trait [519]. The result is ex-
pressed in the form of log of the odds (LOD) score. In this 
model 2 mouse strains of distinct phenotypes are crossed to 
yield F1 and then subsequently F2 progeny [519]. The F2 
generation strains are subjected to genomic scans and link-
age analysis for their genotype determination. This leads to 
the defining of chromosomal map loci by strain specific po-
lymorphic marker, which spans the genome at small intervals 
[519]. After this initial mapping, secondary congenic lines 
are created by repeated intercrossing of inbred strains that 
differ significantly in the measured phenotypes to isolate the 
QTL locus from one strain onto the genetic background of 
another strain [519]. Recombinants selection helps in nar-
rowing down the QTL locus for the identification of strain 
specific polymorphism and functional expression difference 
in specific genes [519]. Major disadvantage of this technique 
is that it is laborious and many intercrosses for determination 
of genotypes and phenotypes of hundreds and or thousands 
of mice. This may take years for analysis. 
IN SILICO QTL MODEL 
 This model takes advantage of the mouse SNP database 
containing allele information of 15 inbred mouse strains [15, 
519, 520]. Phenotype data of a particular trait is analyzed 
against the SNP database for the identification of SNP pat-
terns that are similar among strains with similar phenotypes, 
but different among strains with different phenotypes [15, 
519]. A further analysis is done to pin point the gene and 
mutation within the QTL [15, 519]. Critical advantages of 
this model includes reduced time of analysis and quick gen-
eration of data, no intercrosses to be performed and by the 
help of this model multiple strains instead of just 2 in classi-
cal QTL analysis can be analyzed [15, 519]. Using this 
model already 5 genetic loci associated with atherosclerosis 
in ApoE-/- mice have been defined [15, 519]. As a conse-
quence of the sequencing of the mouse genome and avail-
ability of a more detailed mouse SNP database this model 
will get high impetus.  
 In silico method has the limitation due to the unequal 
distribution of marker information but with the increasing 
number of SNPs in the database this will be less of a prob-
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lem in the near future. This method also fails to account for 
the epistatic genetic interactions and may also not detect 
phenotype-altering mutations that occurred after the strains 
diverged from each other since it relies on evolutionary de-
rived genetic differences between the strains [15, 519]. 
PROCESS OF ATHEROSCLEROSIS AS MODEL 
 The process of atherosclerosis consists of many steps, 
which can be used to study atherosclerosis progression and 
the protective effect of test compounds, as discussed below. 
Reverse Cholesterol Transport 
 This important process of atherosclerosis can be moni-
tored by evaluating the activities of various proteins facilitat-
ing it. These include Apo A, HL, PLTP, CETP, HDL, 
ABCA1, to name a few. An increase in this process should 
ultimately increase the plasma HDL levels [61, 62, 521], 
which can be estimated by regular methods [521-523]. Ani-
mal models of atherosclerosis can be screened in the pres-
ence or absence of test compounds for increased level of 
plasma HDL and improvement in LDL/HDL ratio [524]. The 
LXR agonist T0901317 promotes the RCT from macro-
phages by increasing plasma efflux potential [523]. RADAR 
(Rosuvastatin and Atorvastatin in different Dosages And 
RCT) study showed that 10, 20 and 40 mg of rosuvastatin 
was significantly more effective than 20, 40 and 80 mg of 
atorvastatin in improving the LDL-C/HDL-C ratio in patients 
with cardiovascular disease and low HDL-C. However both 
drugs showed similar and significant increase in HDL-C 
levels [61, 525]. Since it is expected that an activation of the 
RCT pathway will ultimately lead to an increase in HDL-C 
levels, the benificial effects on the HDL levels seen in the 
RADAR study may be due the activation of RCT pathway.  
Formation of Atherosclerotic Lesions 
 Assesment of atherosclerotic lesion formation is an im-
portant parameter for evaluating the protective effect of all 
anti-atherosclerotic drugs [42, 526-528]. Atherosclerotic 
animals with and without test compound are sacrificed and 
the aortic arch is removed, cleaned and cut open with the 
luminal surface facing up [101, 529]. It is immersion-fixed in 
10% neutral buffered formalin overnight or 2-3 days [101, 
529]. After rinsing in water, the aortic arch is thoroughly 
cleaned of adventitial fat. The inner aortic surface is stained 
with oil red O (1.0% w/v in 60% isopropanol) for 25 min at 
room temperature. After rinsing with 60% isopropanol and 
distilled water, the aorta is mounted on a glass slide with a 
glass coverslip and aqueous mounting medium containing 
glycerin [101, 529]. The oil red O-stained area was observed 
using zoom microscope and stained area was analyzed by 
image analysis software [101, 529]. Immunohistochemistry 
with macrophage, T cell or VSMC specific and inflamma-
tory marker tells about the composition of the lesion [530-
532]. In human advanced imaging techniques are required 
for monitoring lesion progression and regression [533]. On 
the basis of above parameters, statins have been shown to 
reduce atherosclerotic lesions both in animals and humans 
[236, 534, 535]. 
 
Angiogenesis 
 Besides its overall role in vascular remodeling, neovascu-
larization within the vessel wall plays an important role in 
plaque destabilization and vulnerability [536-538]. Patients 
on statin treatment have reduced intraplaque angiogenesis in 
their carotid endarterectomy specimens when compared with 
patients not receiving this kind of drug [538, 539]. Migration 
and proliferation of endothelial cells in response to VEGF 
play an important role in angiogenesis associated to patholo-
gies such as atherosclerosis, diabetes and tumor development 
[540]. PPAR? agonist fenofibrate suppresses tumor growth 
through direct and indirect angiogenesis inhibition [541]. By 
using HUVEC and chick chorioallantoic membrane (CAM) 
models in vitro and in vivo respectively, angiogenesis can be 
evaluated in the presence of test compounds [540]. In this 
model fertile eggs are cracked on Day 4 of incubation and 
individually cultured in a covered glass dish at 37°C and 3% 
CO2 in air and saturated humidity. Test substances are ap-
plied to the surface of the CAM within silastic rings. Digital 
images of the live CAM are captured using a binocular dis-
section microscope [542]. Similarly HUVEC cells are seeded 
on Matrigel and formation of vascular (tube) like structures 
is monitored in the presence or absence of test compounds. 
Pictures are taken by microscope and degree of cord forma-
tion is quantified by measuring the area and length occupied 
by the tubes [543-545].  
Cell Differentiation 
 Since differentiation of monocytes to macrophages is one 
of the most important events of atherosclerosis, candidate 
drugs inhibiting this process can be suitable for atherosclero-
sis treatment [546]. For this assay, various monocytic cell 
lines like THP and Raw 264.7 can be taken. Cells are differ-
entiated in presence of phorbol 12-myristate 13-acetate 
(PMA), Ox-LDL, MCSF or GMCSF [5-7, 547-551]. Up 
regulation of differentiation markers like CD11, CD14, type-
I SR can be monitored for assessing differentiation [552-
554]. In case of floating cells like THP, induction of differ-
entiation leads to their attachment and this can be monitored 
biochemically or microscopically. In vivo differentiated 
macrophages can be detected by staining immunochemically 
with differentiated cell specific markers [532]. Lovastatin (5-
15 ?M) caused a significant dose-related reduction in steady 
state levels of type-I SCR mRNA in PMA-treated THP-1 
cells [552].  
Macrophage Foam Cell 
 Peritoneal animal macrophages or PMA differentiated 
THP cells are treated with Ox-LDL (40-100 μg/ml) for 24-48 
h in the presence or absence of test compound [6, 7, 383]. 
Cells are stained with Oil Red O to assess the amount of 
lipid inside the cell [555, 556]. This can be assessed spectro-
photometrically at 518 nm also after lysing the cells [216]. 
Cell surface receptors like CD36, SRA or LOX-1 can be 
monitored for increased macrophage foam cell formation [6]. 
An inhibition in their expression reflects in the inhibition of 
the process of atherosclerosis. Similar immunohistochemical 
staining can be done in animal aortic tissues [6, 101, 529, 
532, 557]. Atorvastatin-mediated inhibition of macrophage  
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foam cell is accompanied by inhibition of Ox-LDL induced 
increase in the expression of SR CD68 and that of fatty acid 
binding protein 4 [558]. 
Leukocyte Migration Assay 
 This can be set up as any other migration assay. For as-
sessing the migration of cell in response to endothelium acti-
vation, THP-1 monocyte migration can be assayed by using 
the ChemoTx kit (Neuro Probe) or Boyden chambers [559]. 
The lower chamber is filled with medium obtained after Ox-
LDL or TNF-? treatment of endothelial cells (HUVECs). 
Monocytes are incubated in the presence or absence of test 
compound and after incubation for around 6h at 37°C; cells 
that migrate into the lower chamber are counted by flow cy-
tometry or conventional methods [557]. Test agents like KR-
31378 have been found to inhibit monocyte recruitment 
[557]. Simvastatin inhibits the migration and adhesion of 
monocytic cells and disorganizes the cytoskeleton of acti-
vated endothelial cells [560]. Lovastatin inhibits endothelial-
monocyte cell interaction by down-regulating the expression 
of VCAM-1 and E-selectin by inhibiting the phosphoinosi-
tide 3 kinase (PI3-kinase)/protein kinase B (Akt)/NF-kappaB 
pathway in endothelial cells [561]. Similar types of assay can 
be set for SMCs [559]. 
Proliferation Assay 
 Macrophage proliferation
 
can be determined by counting 
the numbers of macrophages 24 h after
 
exposing them to 
varying concentrations of the drug, as described earlier [562, 
563]. Briefly, peritoneal
 
macrophages can be harvested and 
allowed to adhere in 6-well plates
 
for 2 h [564]. Candidate 
drug can be added to 2 x 10
5
 cells in siliconized polypropyl-
ene
 
tubes. After
 
overnight incubation, 10 ?l of trypan blue 
solution is added to each tube followed by gentle shaking 
during incubation,
 
for 2 min, and a 10-?l aliquot can be used 
for counting the
 
number of cells in a hemocytometer. Prolif-
eration can also be studied using MTT assay using MTT kit 
from ATCC following manufacturer’s protocol [565]. 
Briefly, after plating the cells for 6-24 h, 10μl of MTT rea-
gent is added followed by incubation for 2-4 h until a purple 
precipitate is visible. This is followed by addition of 100 μl 
of detergent reagent and left at room temperature for 2 h 
[565]. Absorbance is read at 570 nm. Simvastatin, lovastatin 
and mevastatin inhibit proliferation and invasion of mela-
noma cells [566]. Pitavastatin inhibits LPA-induced prolif-
eration and MCP -1 expression in aortic SMCs [567]. 
Cell Adhesion Assay 
 Adhesion of THP-1 cells to HUVEC cells can be assayed 
as previously described [559, 568]. Briefly, HUVEC cells 
can be plated in a 6 well culture plate at a cell density of 
1x10
5
 per well and cultured to 90% confluency. The cells 
can be treated with various drugs for appropriate times. 
THP-1 (2x10
4
 cells/ml) cells in an exponential growth phase 
is added to each well and incubated with HUVEC cells for 
30 min at 37
0
C.The unbound cells are washed 3 times with 
the RPMI media and the total number of cells adhered are 
counted randomly in 4 randomly selected optical fields per 
well. Fluvastatin, inhibits expression of adhesion molecules 
on human monocyte cell line [569]. Similarly adhesion of 
platelets can be done in presence or absence of test com-
pound by performing static or flow adhesion assays [570]. In 
these assays washed platelets are added to laminin, collagen, 
fibrinogen or fibronectin-coated plates [571, 572]. Unad-
hered platelets are washed off and adhesion can be calculated 
by doing simple protein estimation of the adhered platelets 
[573, 574]. Under flow condition, platelet adhesion is moni-
tored by using parallel plate rectangular perfusion chamber. 
Prewarmed blood is perfused through the chamber by the 
help of a peristaltic pump [571]. Platelets adhered in the 
presence or absence of test compound can be monitored mi-
croscopically [571]. Inhibition in platelet adhesion during the 
process of atherosclerosis and restenosis is an attractive 
therapeutic strategy being pursued actively. 
Apoptosis Assays 
 Apoptosis can be quantified by common staining by 
Hoechst
 
H33342 and propidium iodide using immuno fluo-
rescence microscopy as previously described [575]. Nuclei 
of apoptotic cells will be stained brightly with
 
H33342 dye 
and stained negatively with propidium iodide. Analysis
 
can 
be done using conventional tool programmes. Apoptosis
 
can 
also be confirmed with a DNA laddering assay, as previously 
described [576]. Intracellular caspase-8 and -9 can be meas-
ured
 
using a colorimetric assay with p-nitroaniline-labeled 
substrates,
 
as previously described [576] or by western blot-
ting. Apoptosis can also be measured by Flow Cytometry 
using AnnexinV and PI dyes. Briefly, the cell size and PS 
(phosphatidylserine) exposure is analyzed by flow cytometry
 
using a fluorescence activated cell sorter (FACS) and appro-
priate software. PS exposure is estimated by FITC- or Cy3-
conjugated Annexin
 
V staining [577]. FITC- and Cy3-
Annexin V can be purchased from commercial vendors 
[577]. Candidate drug treated THP-1, VSMC cells can be 
analyzed for apoptosis studies. Lovastatin-induces apoptosis 
in macrophages through the Rac1/Cdc42/JNK pathway [578] 
and lipophilic statins induce apoptosis of human VSMCs 
[579]. 
Thrombosis Potential 
 Thrombosis goes hand in hand with atherosclerosis and 
blood coagulation, platelets and endothelium contribute to 
this [38, 580]. Since platelets are involved in atherosclerosis 
progression as well as thrombus formation [581], so assess-
ment of platelet behavior in hypercholesterolemic condition 
provide an important tool to predict atherogenicity of the 
subject/model. Commonly available parameters/methods of 
assaying platelet function are, optical (turbidometric), im-
pedance and whole blood platelet aggregometry [582-584], 
platelet activation markers (such as platelet-activating factor-
4 [585], ?-thromboglobulin [586-588], P-selectin [589, 590], 
CD63 [591, 592], CD40L [593, 594], conformational chan-
ges in the GPIIb/IIIa receptor [595-597], binding of secreted 
proteins (thrombospondin) [598] and Platelet Function Ana-
lyzer-100 (PFA-100) [581]. Platelet-mediated, thrombin re-
lease [599], augmented plasma fibrinogen level [600] and 
low level of antithrombin-III [601-604], reflect the hyperco-
agubility of blood in hyperlipidemic condition [600]. The 
status of coagulation pathways/factors can be evaluated by 
estimating the coagulation parameters which include throm-
bin time (TT), prothrombin time (PT), activated partial 
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thromboplastin time (aPTT), fibrinogen time (FT) by coagu-
lation analyzer [605, 606]. The hemostatic markers (fibrino-
gen, vWF, antithrombin –III, plasmin-antiplasmin com-
plexes, thrombin-antithrombin complexes) can be assayed by 
commercially available assay kits [607]. The effect of niacin, 
warfarin and antioxidant vitamin cocktail on coagulation 
parameter has been evaluated in peripheral arterial disease 
patients [608]. The effect of hormonal regulation on hemo-
dynamic parameters and atherosclerotic risk factors have 
also been assessed in womens taking progestin containing 
contraceptives [606], and testosterone treated rabbit model 
[609]. Besides this many animal models of thrombosis are 
also available which can be used to assess the hyperco-
aguability and thrombogenecity of blood under hyperlipi-
demic conditions in the presence and absence of test com-
pounds [339, 340, 445, 610-612].  
Autophagy Assay 
 Autophagy is a process that directs cytoplasmic material 
and organelles to the lysosomes. In this process, portions of 
cytosol and organelles are encircled by autophagosomes. 
This is followed by fusion between autophagosomes and 
endosomes/lysosomes, culminating in the formation of 
autolysosomes and degradation of their contents [613, 614]. 
Since autophagy is more for survival than death, its occur-
rence in VSMC may increase plaque stability however at the 
same time in macrophages it may be detrimental [615]. The 
classical ways to measure autophagy are quantitative elec-
tron microscopy and the degradation rate of long-lived pro-
teins in presence of standard autophagy inhibitor (3-
methyladenine or wortmannin) [616]. An assay developed by 
Seglen measures the sequestration of a soluble cytoplasmic 
marker to a membrane-bound and thus sedimentable cell 
fraction [617, 618]. Microtubule-associated protein 1 light 
chain 3 (LC3) was introduced as the first protein that local-
ises specifically to autophagosome membranes and can be 
detected by conventional microscopy or western blotting in 
the presence and absence of test compounds [619].  
Phagocytosis Assay 
 Phagocytosis has varied implications in atherosclerosis 
[6]. Phagocytic efficiency of monocytes can be assessed by 
monitoring uptake of labeled (fluorescein) bacteria, yeast, 
AC (apoptotic cell), lipids in simple in vitro test systems 
[620-622]. Adherent Cells are incubated with S. cerevisiae in 
the presence or absence of test compund like pravastatin in a 
wet chamber for 30 min at 37 °C in 5% CO2 in air [621, 
622]. Washing is done to eliminate non-phagocytosed S. 
cerevisiae, followed by fixation staining with 10% buffered 
Giemsa solution. The number of S. cerevisiae that are at-
tached/ ingested are assessed by optic microscopy. The 
phagocytic index is calculated as the average number of at-
tached plus ingested S. cerevisiae per phagocytosing mono-
cytes, multiplied by the percentage of these cells engaged in 
phagocytosis [620]. A recent study found that pravastatin 
was able to decrease phagocytosis through complement re-
ceptors and caused a decrease in the production of hydrogen 
peroxide by monocytes. This may contribute to the inhibition 
of plaque development and instability [621]. 
 
Plaque Rupture 
 Atherosclerotic plaque rupture is the root cause of 
atherothrombosis disorders. No single model shows excel-
lence in plaque rupture homology with human, but the mod-
els in focus are swine, rabbit, rat and mouse [623]. Sponta-
neous plaque rupture and hemorrhage is seen in pigs with 
inherited hyper-LDL cholesterolemia bearing mutant alleles 
for ApoB, however these complications occur in 39-54 
month old animals [272, 623]. Swine model offers several 
advantage, for example imaging studies for the assessment of 
lesion site (and size), vulnerable plaque component and 
plaque stabilizing therapies can be easily applied [224]. 
Aged (42-54 week) ApoE deficient mice [624] develop in-
terplaque hemorrhage and plaque instability features [624], 
and this process is accelerated by feeding westernized diet in 
ApoE deficient mice [265]. One study found spontaneous 
death in 37–59 week-old ApoE deficient mice fed with diet 
containing 21% lard and 0.15% cholesterol [625]. CETP 
transgenic Dahl salt sensitive hypertensive rat model pro-
posed for plaque rupture is characterized by hypertriglyc-
eridemia, hypercholesterolemia, decreased HDL, lesions in 
aorta and coronary vessels, premature death due to myocar-
dial infarction (MI). Although plaque rupture is not observed 
but occurrence of MI indicate the potential of this model for 
coronary artery plaque rupture [626]. Induced plaque rup-
ture/thrombosis can be attained in models by various ma-
nipulations. High cholesterol high fat diet fed rabbit models 
manipulated with balloon injury develop plaque rupture 
[227]. This has several advantages which include reproduci-
ble plaque formation on balloon surface, measurable me-
chanical strength and delivery of gene, genetically modified 
cells, proteins, lipids from outside for studying the role of 
various factors on plaque stability and fissuring [227]. Major 
limitation in this model is requirement of high cholesterol/fat 
diet for long time, around 8 months. Another means of in-
ducing plaque rupture in cholesterol fed rabbit is to simulta-
neously treat them with Russell’s viper venom followed by 
the vasopressor histamine [627, 628]. Knockout mouse 
model, ApoE deficient and ApoE-LDLR double knockout 
are being used as a model for spontaneous plaque rupture 
[629, 630]. Various manipulations have been used to induce 
plaque rupture in ApoE deficient mice. These include photo-
chemical injury to mice vessels [20, 631], 9 week feeding 
with cholesterol and fat rich diet coupled with shear induc-
tion by pericarotid device (perivascular shear stress modifier) 
[632], implantation of perivascular cuff followed by p53 
adenovirus transfection and pressor challenge with phen-
ylephrine [633], common carotid ligation followed by poly-
ethylene cuff placement [629], mechanical injury (compres-
sion of abdominal aorta with blunt forceps) [634] and peri-
vascular carotid collar implantation in western type diet fed 
mice [635].  
MOLECULAR TARGET ASSAYS 
 A defined molecular target is one of the characteristic 
features of a successful drug. Candidate drug molecules can 
be screened against defined targets by performing simple in 
vitro assays in the lab (Table 1A, 1B & 1C). A list of current 
and potential new drug targets in atherosclerosis is listed 
(Table 1A, 1B & 1C). The principle and the assay type of 
these targets are briefly mentioned and suitable references 
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Table 1A. Molecular Targets and Assays 
 Target Pathway Response Method 
1 PPAR? Multiple including, 
Inflammation & 
RCT 
Expression, 
Promoter activity 
Electrophoretic mobility shift assay (EMSA) [636], Luciferase assays 
[637], RT-PCR [638], Immunoblotting [636], FACS [639] 
2 PPAR? Multiple including, 
Inflammation & 
RCT 
Expression, 
Promoter activity 
EMSA [640], Luciferase assays [641], RT-PCR [642], Immunoblotting 
[640] 
3 LXR Multiple including, 
Inflammation & 
RCT  
Expression, 
Promoter activity 
EMSA [643], Luciferase assays, RT-PCR [642], Immunoblotting [643] 
4 Apo A RCT (HDL compo-
nent) 
Expression, 
Promoter activity/levels 
Luciferase assays [644], liquid-phase double-antibody radio immunoassays 
rocket immunoelectrophoresis [645] 
5 ABCG1 Cholesterol efflux 
(RCT) 
Expression, 
Promoter activity 
Immunoblotting [105], RT-PCR [646] 
6 CD36 Foam cell formation Expression, 
Promoter activity 
Luciferase assays, RT-PCR [647], Immunoblotting [648], FACS [649] 
7 SRA Foam cell formation Expression, 
Promoter activity 
Luciferase assays, RT-PCR, Immunoblotting [648], FACS [650] 
8 COX-2 Inflammation, free 
radical generation 
Enzymatic activity for AA 
metabolism to PG  
synthesis, 
Expression 
Spectrophotometric [651], Immunoblotting [652], Colorimetric & 
flourimetric immunoassay, ELISA [651] 
9 NOS Inflammation, free 
radical genera-
tion,vasodilation 
Enzymatic activity for 
Nitrite formation, NO 
release, 
Expression 
ELISA, radioactive, colorimetric NOS assays [653-655] 
10 RXR Multiple including, 
Inflammation & 
RCT 
Promoter activity, 
Expression 
Luciferase assays [656], RT-PCR [657], Immunoblotting [639] 
11 MIF Adhesion, migration, 
proliferation, In-
flammation 
Quantity/level Antibody based immunoassay, ELISA [658], FACS [658] 
12 HL RCT Enzymatic activity for fatty 
acid release, triglyceride 
substrate 
Fluorimetric substrate utilization, Radioactive assay [659,  660] 
Table 1B. Molecular Targets and Assays (Continued) 
 Target Pathway Response Method 
13 ICAM Adhesion Expression,levels EMSA, Luciferase assays, RT-PCR, FACS [661], Immunoblotting, ELISA 
[662] 
14 VCAM Adhesion Expression, levels EMSA [663], Luciferase assays [663], RT-PCR [663], FACS [664], Im-
munoblotting [663], ELISA [662] 
15 ACAT-1, 2 Foam cell  Enzyme activity, 
[14C]oleate incorporation 
into cholesterol esters, 
expression 
Radioactive assays [665, 666], ACAT activity and immunoblotting, 
RTPCR [666, 667] 
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(Table 1B) contd…. 
 Target Pathway Response Method 
16 SRB1 Cholesterol efflux, 
RCT 
Expression, levels RT-PCR, Immunoblotting [668], FACS [669] 
17 Free radi-
cals 
Formation of modi-
fied lipids, oxidative 
stress 
Generation of ROS&RNS FACS-DCF&DAF response [670] 
18 5-LOX Formation of modi-
fied lipids,infla-
mmation 
Expression & Enzyme 
activity for hydroperoxides 
generated from the incuba-
tion of a 5-, 12-, or 15-LOX 
with either AA or LA 
Spectrofluorimetric [671-673], Western blotting and Luciferase assay [674] 
19 CD68  Foam cell formation Expression, levels RT-PCR [675], Immunoblotting, FACS [675] 
20 MMP, 
MMP3 
Plaque rupture Enzyme activity for prote-
olytic cleavage self 
quenched peptide leading to 
enhanced flourescence post 
cleavage, Expression 
Fluorimetric detection, immunoassay, immunoblotting. [676] 
21 ABC-
A1,A2 
Cholesterol efflux, 
RCT 
Cholesterol efflux, RCT EMSA, Luciferase assays, RT-PCR FACS, Immunoblotting [646] 
22 LOX-1 Lipid uptake, foam 
cell 
Promoter activity, 
Expression 
RT-PCR, Immunoblotting [677] 
23 PLTP  RCT Enzyme activity, transfer of 
donor fluorescent self-
quenched phos pholipid to 
an acceptor leading to an 
increase in fluorescence, 
radioactive [14C] phos-
phatidylcholine from phos-
pholipid liposome (PL 
donor) to HDL acceptor 
Fluorimetric assay [678-681] 
Table 1C. Molecular Targets and Assays (Continued) 
 Target Pathway Response Method 
24 CXCR2, 
CXCR1 
Cell infiltration, In-
flammation 
Promoter activity, 
Expression 
RT-PCR [682], Immunoblotting [683], FACS [684] 
25 TXA2 Inflammation, platelet 
activation 
TXB2 levels Spectrophotometric [685], ELISA [686]  
26 mTOR Proliferation Kinase activity, incorpora-
tion of phosphate 
Radioactive [281], Spectrophotometric, ELISA [687,688] 
27 CETP RCT CETP mediated transfer of 
donor molecule containing 
flu-orescent self quenched 
neutral lipid (from HDL) to 
acceptor molecule 
(LDL&VLDL) giving 
enhanced fluorescence, 
expression 
Fluorimetric ELISA [689-692], Expression [693] 
28  HDL RCT Quantity/levels ELISA photometric [694] 
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(Table 1C) contd…. 
 Target Pathway Response Method 
29 LOX 15 Formation of modified 
lipids 
Enzyme activity, hydrop-
eroxides generated from 
the incubation of a 5-, 12-, 
or 15-LOX with either AA 
or LA 
Spectrophotometric, ELISA [695-697] 
30 CD-14 Inflammation Promoter activity, 
Expression 
Luciferase assays, RT-PCR [698], Immunoblotting [699], FACS [700] 
31 Cx 37 (gap 
junction) 
Adhesion Expression RT-PCR, Immunoblotting [701] 
32 Phospho 
lipase A2 
Inflammation, RCT Enzyme activity, free thiols 
generated from specific 
substrate in presence of 
PLA2 are detected using 
DTNB reagent  
Spectrophotometric ELISA [702-704] 
33 HMG-CoA 
Reductase 
Cholesterol synthesis Enzyme activity, HMG-
CoA dependent oxidation 
of NADPH, generation of 
mevalonolactone in pres-
ence of 14C-HMG-CoA 
Spectrophotometric ELISA, radioactive based assays [705, 706] 
34 LCAT  RCT Release of specific fluores-
cence after LCAT medi-
ated hydrolysis of substrat 
e (transfer of acyl chain 
from the sn-2 position of 
phosphatidylcholine to 
cholesterol) 
Fluorimetric assay [707, 708] 
 
are provided for detailed target specific methodology, which 
will help in setting up the assays in the lab.  
FUTURE STRATEGIES 
 Developing new animal models and understanding the 
mechanism of atherosclerosis along with its complications is 
essential. At the same time emphasis should also be placed 
on selecting the best model suited for screening a particular 
class of drug. Since each model has its own advantages and 
disadvantages, the beneficial actions of a candidate drug 
should be documented in several models of atherosclerosis. 
The protective effect should be evident at the morphological, 
biochemical and molecular levels rather than at single level. 
Preferably a candidate drug should inhibit various processes 
of atherosclerosis and have a defined mechanism of action. 
Strategies like QTL analysis coupled with pharmacogenom-
ics and in silico screening will help in the identification and 
design of new strategies. 
 Important information regarding initiation of atheroscle-
rosis is still not clear. Deciphering the mechanism of athero-
sclerosis will help to address in a major way the side effects 
of various drugs in use. Researchers have to overcome the 
challenge and fact that bigger animals develop better athero-
sclerosis like humans however detailed molecular and ge-
netic studies can be best carried out with smaller animals like 
mice. Secondly since the mouse [709] and human [710] ge-
nome are already sequenced and reagents in the market sup-
port studies in these species, to carry out molecular and other 
detailed studies in other animals often becomes very chal-
lenging. There is an urgent need to have good reagents for 
carrying out molecular studies in all types of animal models 
of atherosclerosis. Developing small animal models, which 
can develop atherosclerosis very similar to humans, can 
bridge the gap between small and big animals. ApoE mice 
and ApoE leiden mice address this issue to some extent [711, 
712]. However we still need a good model of plaque rupture 
and it will be challenging to develop a spontaneous plaque 
rupture model. However it will also be better to have an 
animal model where initiation, progression of atherosclerosis 
is similar to humans. It is also very important that the animal 
develops lesion in area like those in humans. Sometimes the 
drugs are screened on lesions whose sites are not similar to 
humans and despite of showing protective effect in that ani-
mal, no protection may be observed in case of humans since 
the site of lesion is different. Here the flow of blood and 
shear stress may also be important for lesion formation. Im-
aging of small animals is very difficult and there is a need 
for developing sophisticated imaging techniques where ani-
mals can be monitored for atherosclerosis progression or 
regression. Usually a lot of work is based after animal sacri-
fice. Emphasis should be given to develop non-invasive im-
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aging techniques for monitoring progression or regression of 
atherosclerosis. Simultaneously scientists can also develop 
several biomarkers and also surrogate markers for athero-
sclerosis [713]. The development of these markers will 
greatly tell about the mechanism of the diseased and by 
monitoring the levels of the surrogate markers in the animal 
models and also in humans we can easily monitor the effi-
cacy of many drugs. It should also be clear that failure of one 
molecule should not be taken as failure of entire class of 
protein for atherosclerosis treatment. Evidence suggests that 
the effect of a compound may be very specific to its structure 
and mechanism of action [714]. More compounds may be 
designed and synthesized using information from the crystal 
structure of their protein. At the same time the compound 
should be tested in various models of atherosclerosis both in 
vivo and in vitro. By doing computational analysis of murine 
SNP database and utilizing data from inbred parental strains, 
can lead to rapid identification of QTL intervals. Computa-
tional identification of putative disease genes can be done by 
coupling information from murine SNP database, tissue spe-
cific gene expression database and phenotypic information 
across mouse strains as discussed in the review. Good use of 
QTL and in silico analysis will reduce the time for identifica-
tion of genes involved in atherosclerosis progression. Since 
several mechanisms are responsible for the development of 
atherosclerosis, it is most likely that a combinatorial therapy 
may work in atherosclerosis rather than one alone.  
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LIST OF ABBREVIATIONS 
AA = Arachidonic acid 
ABCA1 = ATP-binding cassette transporter A1 
ABCG1  = ATP binding cassette transporter G1 
ACAT  = Acyl-CoA:cholesterol acyltransferase 
AcLDL = Acetylated LDL 
AngII  = Angiotensin II 
Apo = Apolipoprotein 
ASBT = Apical sodium dependent bile acid transpor-
ter 
CAM = Chick chorioallantoic membrane 
CCR2  = C-C motif chemokine receptor–2 
CETP  = Cholesterol ester transfer protein 
CHF = Congestive heart failure 
COX = Cyclooxygenase 
CRP = C reactive protein 
Cx  = Connexin  
ELAM = Endothelial-leukocyte adhesion molecule 
ELISA = Enzyme-Linked ImmunoSorbent Assay 
EMSA  = Electrophoretic mobility shift assay 
eNOS = Endothelial nitric oxide synthase 
EPCs = Endothelial progenitor cells 
FACS = Fluorescence activated cell sorting 
FLAP = Five lipoxygenase activating protein 
G-CSF  = Granulocyte colony stimulating factor 
GM-CSF  = Granulocyte macrophage colony-stimulating 
factor 
5-HT = 5-Hydroxytryptamine 
HDL  = High-density lipoprotein 
HFN-4? = Hepatocyte nuclear factor-4? 
HL = Hepatic lipase 
HMGCoA  = 3-hydroxy-3-methylglutaryl coenzyme A 
HOPE  = Heart Outcomes Prevention Evaluation 
HUVEC = Human umbilical vein endothelial cells 
ICAM  = Intercellular adhesion molecule 
IFN-? = Interferon gamma 
IL = Interleukins 
iNOS = Inducible nitric oxide synthase 
IP-receptor = PGI2 receptor 
JAM-A  = Junctional adhesion molecule-A  
JNK = c-jun-N-terminal kinase 
LA  = Linoleic acid 
LDL = Low-density lipoprotein 
LDLR = Low density lipoprotein receptor 
LOD = Log of the odds 
LOX  = Lipoxygenase 
LOX-1  = Lectin-like oxidized low-density lipoprotein 
receptor-1 
Lp(a) = Lipoprotein (a) 
LPA  = Lysophosphatidic acid 
LPL = Lipoprotein lipase 
LXR = Liver X receptor 
MCP  = Macrophage chemotactic protein 
M-CSF  = Macrophage-colony stimulating factor 
MHC = Major histocompatibility complex 
MIF  = Migration inhibitory factor 
MIG = Gamma interferon-induced monokine 
MIP = Macrophage inflammatory protein 
MMPs  = Matrix metalloproteinase 
mTOR  = Mammalian target of rapamycin 
NF?B  = Nuclear factor-kappa B 
NHPs = Non-human primates 
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NKT = Natural killer T cells 
NO  = Nitric oxide 
NZW = New Zealand White 
Ox-LDL = Oxidized LDL 
PAF = Platelet activating factor 
PAI-1 = Plasminogen activator inhibitor-1 
PASMC = pulmonary artery smooth muscle cells 
PDGF = platelet-derived growth factor 
PECAM-1  = Platelet/endothelial cell adhesion molecule-1 
PGs = Prostaglandins 
PGH2  = Prostaglandin H2 
PGI2 = Prostacyclin 
PI3 Kinase = Phosphoinositide 3 (PI3) kinase  
PKC = Protein kinase C 
PLA2 = Phospholipase A2 
PLTP = Phospholipid transfer protein  
PMA = Phorbol 12-myristate 13-acetate 
P
38
MAPK  = P
38
mitogen activated protein kinase 
PMN = Polymorphonuclear leukocytes 
PPAR  = Peroxisome proliferator-activated receptors 
QTL  = Quantitative trait loci 
RADAR  = Rosuvastatin and Atorvastatin in different 
Dosages and RCT 
RANTES = Regulated upon activation normal T-cell 
expressed and secreted  
RAS  = Renin-angiotensin system 
RCT  = Reverse cholesterol transport 
RNS = Reactive nitrogen species 
ROS = Reactive oxygen species 
RT-PCR = Reverse transcriptase- polymerase chain 
reaction 
SHR = Spontaneously hypertensive rats 
SHR-SP = Stroke-prone spontaneous hypertensive rats 
SMC  = Smooth muscle cell 
SNP  = Single nucleotide polymorphism 
SR = Scavenger receptor 
STZ = Streptozotocin 
TF = Tissue factor 
TFPI = Tissue facor pathway inhibitor 
TGF ? = Transforming growth factor ? 
Th = T helper cells 
THP-1 = Human acute monocytic leukemia cell line 
TLR = Toll-like receptor 
TM = Thrombomodulin 
TNF = Tumor necrosis factor 
TNFR-I = Tumor necrosis factor receptor-I 
TP  = Thromboxane prostanoid 
tPA = Tissue plasminogen activator 
TX = Thromboxane 
uPA = Urokinase-type plasminogen activator 
VCAM  = Vascular cell adhesion molecule  
VLA-4  = Very late antigen-4 
VLDL = Very low density lipoprotein  
VSMC = Vascular smooth muscle cell 
vWF = Von Willebrand factor 
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